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ABSTRACT
TRANSCRIPTIONAL REGULATION OF THE CHICKEN APOLIPOPROTEIN A-I
GENE EXPRESSION
Wen Lin Kumfert 
Eastern Virginia Medical School, 2000 
Director: Timothy J. Bos
Deregulation of a set of critical cellular genes has long been speculated as a cause 
of the oncogenic transformation induced by v-Jun oncoprotein. In the past several years, 
extensive efforts have been made to identify such genes. Several target genes have been 
identified that are specifically associated with the v-Jun induced transformation 
phenotype in chicken embryo fibroblasts (CEF).
We have undertaken the objective to identify and characterize the genes that 
become deregulated in response to, or as a consequence of, Jun-induced transformation. 
By exploiting the difference in oncogenic potential between v-Jun and c-Jun in CEF, the 
chicken apolipoprotein A-I (apoA-I) gene has been identified in our laboratory as one of 
the target genes whose expression is repressed in response to v-Jun overexpression in 
CEF. The overall objective of this study is to investigate the underlying molecular 
mechanisms by which the apoA-I gene expression is regulated, especially by the v-Jun 
oncoprotein.
In this study, we mapped the v-Jun responsive elements within nucleotides -311 
to +19 upstream of the apoA-I transcription start site. Biochemical analysis of functional 
domains of v-Jun indicates that DNA binding specificity of v-Jun and its ability to 
heterodimerize with diverse partners are absolutely required for repression of apoA-I 
transcription. Further, the sequences between amino acid residues 108 to 128 in the 
amino terminus of v-Jun proteins that contains the acidic region III o f its transactivation
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
domain are important for its repressor activity. In addition, an enhancer located between 
-6.8 kb to -6.0 kb upstream o f the transcription start site of the apoA-I gene was 
identified and characterized. The enhancer is capable of stimulating transcription from 
the apoA-I promoter in a distance- and orientation-independent manner and is CEF- 
specific. Sequence information o f the enhancer revealed that it is 791-bp long and 
contains many putative binding sites for known transcription factors. Deletion analysis 
of the enhancer activity indicates that there are many modules, both positive and 
negative, located within the 791-bp enhancer region. Nuclear transcription factors Spl, 
C/EBP, HNF-3, and an unknown factor were found that might interact with the cis-acting 
elements of the enhancer.
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Jun: transcription factor and oncoprotein
Oncogene v-jun, and its cellular counterpart, c-jun, code for a major component of 
the transcription factor complex activator protein 1 (AP-1). AP-1 was originally defined 
as a DNA-binding activity recognizing the TPA (12-O-tetradecanolphorbol-13-acetate) 
response element (TRE) and responsible for transcriptional induction o f a number of 
genes in response to activation of protein kinase C (PK.C). After molecular cloning 
revealed that Jun is a major component o f AP-1, Jun has been shown to bind specific 
DNA sequences and transactivate transcription of many genes. Ever since its 
identification, the role of Jun in transcriptional regulation and in oncogenesis has been the 
subjects of intensive study. Significant progress has been made in understanding the 
complexity of Jun regulation.
Cloning o f v-Jun, c-Jun, and related proteins
The viral oncogene v-jun was originally isolated as the transforming gene from 
avian sarcoma virus 17 (ASV 17), a replication defective retrovirus isolated from a 
spontaneous chicken fibrosarcoma (1). Infection with ASV 17 produces sarcomas in 
chickens and transforms cultured chick embryo fibroblasts (CEF) into neoplastic cells 
(2). ASV 17 contains a 930-bp non-viral, cell-derived insert, the jun  encoding sequence, 
that is flanked by gag and env sequences. At the time of its description, no cross-
The model journal used for this dissertation is J  Biol Chem.
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hybridization with known oncogene sequences was found, therefore the gene was given a 
new name.y'w/j, abbreviated from the Japanese ju-nana, meaning “ 17” (1). The presence 
of v-jun homologous sequences in DNA from all vertebrate species examined, suggested 
that v-jun is derived from a cellular proto-oncogene c-jun. In ASV 17 the v-jun 
sequences are fused 3 ’ to gag sequences resulting in the expression of a 65 kDa gag-Jun 
fusion protein. The gag sequences were shown to be dispensable for transformation, 
because a v-jun sequence inserted into a non-transforming avian retrovirus vector, RCAS, 
is transforming both in intact animals and in cell cultures (3). Computer analysis 
indicated that the predicted v-Jun protein contains a region of 60 amino acids adjacent to 
its C-terminus that is 44% identical to the DNA-binding domain o f the yeast transcription 
factor GCN4 (1). The optimal DNA binding sequence of GCN4 is essentially identical to 
that of the mammalian transcription factor AP-1 (activating protein-1) (4,5). These 
findings suggested a possible relationship between Jun and AP-1. Indeed, antibodies 
directed against different regions o f the viral Jun protein strongly reacted with a 39 Kda 
(p39) peptide in an AP-1 preparation purified by affinity chromatography (6-9). 
Bacterially expressed partially purified human c-Jun proteins containing the C-terminal 
DNA binding domain protect the same nucleotides as does purified A P-1 in footprinting 
assays. In addition, overexpression of v-Jun or c-Jun leads to transactivation of 
promoters containing AP-1 binding sites (7,10-12). These key discoveries quickly led to 
the identification of Jun as a component of transcription factor complex AP-1.
Shortly after the cloning of c-jun from human, murine, and avian cells (7,9,13), 
two other closely related proteins were cloned by hybridization of cDNA libraries using 
probes derived from the c-jun carboxy 1-terminus. These two proteins, Jun B (14) and Jun
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D (15,16), are highly homologous to the carboxyl terminus of c-Jun, bind to the same 
DNA binding site and transactivate promoters containing AP-1 sites (14,16). Their 
amino-terminal domains are different from that of c-Jun.
Biochemical Functions o f  Jun
The Jun family proteins have three well characterized structural domains. The 
amino terminus contains transactivation domains. The carboxyl terminus contains a 
highly conserved basic DNA binding domain and an adjacent leucine zipper motif.
These structural domains are responsible for dimerization, specific DNA binding, and 
transcriptional activation/repression (10,12). Fig. 1 shows the structural organization of 
Jun family proteins in relation to the oncoprotein v-Jun.
Dimerization is a prerequisite for Jun to function. The Jun proteins belong to the 
bZIP family o f transcription factors. BZIP transcription factors share a common 
structural motif termed the “leucine zipper”. The “leucine zipper” motif was first 
identified in transcription factor C/EBP (17,18). In transcription factor C/EBP and other 
bZIP proteins, there is a basic domain that mediates binding o f the protein to the major 
groove of DNA while an immediately adjacent amphipathic domain with 4 to 5 leucines 
residues paced at 7 amino acid intervals is responsible for the homo- or 
heterodimerization between bZIP proteins. The leucine zipper region forms an extensive 
a-helix in which every seventh amino acid is a leucine. Due to this arrangment, the 
leucine side chains protrude from one side of the a  helix and form a hydrophobic surface. 
Interdigitation of the leucine side chains facilitates dimerization between two helices 
(18). This periodic array was also noted in the sequences o f the Fos, Jun and GCN4 
proteins (18). The leucine zipper is required and sufficient for dimerization of Jun
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protein which, in turn, is a prerequisite for DNA binding. However, not all bZIP proteins 
dimerize with each other. C-Fos dimerizes with the various Jun proteins but not with the 
bZIP proteins GCN4, or other Fos protein (I I). C-Jun molecules do not heterodimerize 
with GCN4. C-Jun can also form specific heterodimers with the CREB/ATF family of 
transcription factors (19-21). Formation of different complexes depends on the relative 
abundance of each monomer at that particular time. The monomers are differentially 
regulated under various cellular conditions, and different complexes display different 
DNA binding affinities to related but not identical enhancer sequences. In addition, each 
complex can display different transactivation capabilities. The regulatory specificity of 
Jun is dependent on its dimerization partners. That Jun proteins have the ability to form 
homodimers and a large number o f heterodimers with different partners expands the array 
of target genes that are regulated by Jun.
DNA binding specificity - Specific DNA binding activity of Jun is mediated by a 
basic domain immediately adjacent to the leucine zipper (Fig. 1). The amino acid 
sequences of the basic domain are highly conserved among all of the Jun and Fos 
proteins (10). The basic domain is also conserved to a lesser degree in the various CREB 
and ATF proteins that interact with a sequence similar to the TRE (11). Target 
recognition specificity is determined by the monomeric constitution of the dimer. The 
different Jun proteins c-Jun, Jun B and Jun D bind as homo- and heterodimers both to 7- 
bp TREs (TGACTCA) and to 8-bp cAMP-responsive element (CREs) (TGACGTCA) 
(22,23). All members of the Fos family (including c-Fos, Fos B, Fra-1, and Fra-2) 
stimulate binding of the Jun proteins to the TRE-like sequences (12), such as those 
present in human collagenase I, stromelysin, and CD44 genes (5). Heterodimers formed
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.











FIG. I. Structural organization of Jun proteins. Jun proteins 
contain three major structural domains. The acidic domains (filled 
boxes) in the amino-terminal half of the proteins are important for 
transcriptional activation. The basic domain (hatched box) in the 
carboxyl-terminal half of the proteins is responsible for specific DNA 
binding. The adjacent leucine zipper domain (crosshatched box) is 
responsible for dimerization with other bZIP proteins. The dotted box in 
c-Jun indicates the glutamine- and proline-rich region.
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between c-Jun and members o f the CREB/ATF family bind preferentially to CRE-like 
sequences (19-21,24,25). Studies have shown that a new group of conserved coactivators 
increase the specificity o f AP-1 transcription factors (26). One o f these proteins, JAB-1 
(Jun-activation-domain-binding protein 1), interacts with c-Jun and Jun D, but not with 
Jun B or v-Jun. As a result, JAB1 selectively potentiates transactivation by only c-Jun or 
Jun D through specifically stabilizing complexes o f c-Jun or Jun D with AP-1 sites and 
does not affect binding o f either Jun B or v-Jun (26).
Transcriptional regulatory activity -  Apart from the basic domain and the 
leucine zipper motif which are important for DNA binding and dimerization, structure- 
function analysis of the c-Jun protein has identified a potent transactivation domain 
located within the c-Jun amino-terminus (A1 domain) and a less pronounced region 
adjacent to the basic domain (A2 domain) (27). The A 1 activation domain of c-Jun 
consists of three independent acidic regions important for transcriptional activation; I 
(amino acids 6-12), II (amino acids 68-81), and III (amino acids 105 to 120) (Fig. 1) 
(28,29). Regions II and III contain sequences that are also found in the c-fos protein and 
act cooperatively and heterologously to activate transcription (30). Dimerization and 
DNA binding are prerequisites for direct activation of transcription from AP-1 responsive 
promoters. Studies have shown that members of the Jun family of transcriptional 
activators interact with general transcription factors, TBP (TATA-binding protein) and 
TFIIB (31). TBP binds to both the amino-terminal activation domain and carboxyl- 
terminal bZIP regions o f c-Jun, whereas TFIIB binds to only the c-Jun bZIP domain.
This interaction requires the dimerization of the Jun protein (31). In addition, studies 
have also shown that c-Jun proteins interact with CBP (cAMP-responsive-element
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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binding protein binding protein), a coactivator that binds to components of the basal 
transcriptional machinery on one hand and multiple transcription factors on another 
(32,33). Deletion analysis of c-Jun indicates that the CBP binding site is within the 
amino-terminal activation. Loss of binding to CBP in vitro correlates with severely 
reduced transactivation capacity in vivo (33).
Different dimeric complexes have different transactivation capabilities. One 
example is c-Jun and Jun B. Both c-Jun homodimers and Jun B homodimers bind to 
TRE-like sites, and both are capable o f efficiently transactivating genes containing 
multiple TREs in their promoters. However, only c-Jun homodimers are capable of 
stimulating transcription from promoters containing single TRE. Under certain cellular 
conditions, elevated levels of Jun B may lead to the preferential formation of c-Jun/Jun B 
heterodimers which have low binding affinity to single TRE, and this may in turn lead to 
repression of genes controlled by single TRE (34-36).
In addition to direct regulation of transcription from promoters containing AP-1 
responsive sites, Jun can also indirectly regulate transcription from non AP-1 containing 
promoters. In this case, the activity o f a gene may be controlled not only by direct 
binding of a transcription factor to its promoter but also by protein-protein interactions 
between transcription factors, in which only one factor is directly associated with the 
DNA. Jun has been shown to physically interact with non leucine zipper transcription 
factors that recognize completely different consensus DNA sequences, including 
glucocorticoid receptor (GR) (37,38), NFkB (39), Myo D1 (40), Jif (41), and E2A (42). 
Jun modulates the expression o f genes that are responsive to these transcription factors by 
either interfering with their DNA binding ability or altering their transcriptional
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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regulatory properties. Overexpression of c-Jun prevents the glucocorticoid-induced 
activation of genes carrying a functional glucocorticoid response element (GRE). 
Conversely, GR is able to repress AP-1 -mediated transcriptional activation. Direct 
protein-protein interaction is responsible for this mutual inhibition. Mutational analysis 
reveals that the ligand-binding and DNA binding domain o f GR are required for 
repression of Jun/AP-1 activity, and the leucine zipper of c-Jun is required for repression 
of GR activity. While bacterially expressed c-Jun inhibits GR-GRE complex formation, 
GR disturbs AP-1 activity without disturbing the binding o f AP-1 to its binding site 
(37,43). Overexpression o f c-Jun (or c-Fos) enhances the activity o f NFicB-dependent 
genes, and this enhancement depends on the integrity of the NFicB-binding site. 
Conversely, overexpression of NFkB activates AP-1-mediated transcription. This mutual 
transactivation is due to enhanced binding of the transcription factors to either the NFkB 
or AP-1 binding site. The leucine zipper and basic region o f c-Jun or c-Fos are 
responsible for the interaction with NFkB (39). Similarly, c-Jun interacts negatively with 
the muscle specific helix-loop-helix protein Myo D and inhibits myogenic differentiation 
(40). Jif interacts with the leucine zipper of c-Jun and inhibits the DNA binding and 
transactivation potential o f c-Jun in vivo (41). Taken together, through transcription 
factor “cross-talk”, both the repertoire and complexity of Jun transcription regulation are 
increased. Jun can directly regulate the transcription o f genes that contain AP-1 sites and 
indirectly modulate the transcription of genes that do not contain AP-1 consensus 
sequences.
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Regulation o f Jun activity
Regulation o f Jun activity is at transcriptional and posttranslational levels.
Almost all agents known to influence the fate o f cells in culture induce the transcription 
of the c-jun message. These include a number of different growth factors such as platelet 
derived growth factor (PDGF) (44,45), epidermal growth factor (EGF) (46), tumor 
necrosis factor a  (TNFa) (47), a variety of steroid hormones (48), interleukins (49,50), 
tumor promoters, chemical mutagens, ethanol, asbestos, morphines, peroxisome 
proliferators, tamoxifen (51) and certain oxidants and antioxidants (11,12). Many of 
these agents also stimulate transcription of the c-fos gene. The genes c-jun and jun B 
seem to be controlled in a coordinate manner, while jun D appears relatively insensitive 
to most agents controlling cellular proliferation and differentiation (12). Activation o f c- 
jun  transcription by these agents is mainly mediated through specific DNA recognition 
elements in the c-jun promoter. Under certain circumstances, c-Jun itself will positively 
autoregulate its own transcription (52). The positive autoregulation o f Jun is likely to be 
responsible for signal amplification and conversion of transient extracellular signals into 
a long lasting transcriptional response.
The activity o f Jun is regulated by posttranslational modifications. 
Posttranslational modification regulates Jun activity by two means: regulation of binding 
of the protein to the promoter element and, when bound, regulation o f its transactivation 
activity. Two processes positively or negatively affect the DNA binding and therefore 
the transactivation activity of Jun; one is phosphorylation, the other is reduction- 
oxidation.
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Two-dimensional peptide maps and phosphoamino acid analysis revealed that 
serine 243, serine 249 and threonine 239 located directly upstream of the basic DNA 
binding region of the c-Jun protein were phosphorylated in vivo (53). Glycogen synthase 
kinase-3 (GSK-3) was shown to phosphorylate the two serine and one threonine residues 
of bacterially expressed c-Jun in vitro (53). A c-Jun protein in which serine 243 has been 
replaced with phenylalanine or alanine, mutations which interfere with phosphorylation 
at all other sites, binds better to DNA and is a much stronger transactivator in vivo than 
the wild type protein (53). Other studies have shown that phosphorylation at carboxyl- 
terminal residue serine 243 of human c-Jun (which corresponds to chicken serine 226 and 
serine 216 in v-Jun) (see Fig. 2) is correlated with low DNA binding ability of the c-Jun 
protein (53). Treatment with TPA or other stimulatory agents dephosphorylates this 
serine site and increases DNA binding activity of AP-1 (11). In the oncogenic v-Jun 
protein, this serine (serine 216) is replaced by a phenylalanine, one of only two amino 
acid changes in the carboxyl-terminal domain of the protein which distinguish c-Jun from 
v-Jun (11,12) (see Fig. 2).
The target for redox regulation is cysteine 269 (which corresponds to cysteine 252 
in the chicken c-Jun and cysteine 242 in v-Jun, see Fig. 2). Reduction of this residue by 
chemical oxidizing agents or by a ubiquitous nuclear redox factor (Ref-1) stimulates Jun 
DNA binding activity in vitro, whereas oxidation or chemical modification of the 
cysteine has an inhibitory effect on DNA binding activity (54,55). Very recent studies 
show that Ref-1 mediates the activation of c-Jun in HeLa and NIH 3T3 cells in response 
to heat shock and modulates the AP-1 stress response in the rat conceptus (56,57).
























FIG. 2. Structural differences between chicken c-Jun and v-Jun.
There are several structural differences between chicken c-Jun and v-Jun. 
V-Jun contains a 220 amino acid gag encoded leader, a deletion of 27 amino 
acid region (delta region) in the amino-terminus, and two non-conservative 
point mutations in the carboxyl terminus. The 220 aa Gag leader sequences 
are dispensible for transformation. The truncated v-Jun, VJ-1, is used in this 
study as transforming oncoprotein v-Jun.
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Interestingly, in the oncogenic v-Jun protein, this cysteine residue is mutated to serine. 
These two mutations render v-Jun non-susceptible to negative regulation (Fig. 2).
The activity o f Jun is also regulated by phosphorylation in the amino-terminal 
transactivation domain. Phosphorylation of the two serine residues in the transactivation 
domain of c-Jun, serine 63 and serine 73, increases the transactivation activity of c-Jun 
(58,59). This phosphorylation is mediated by Jun N-terminal kinases JNK (or stress- 
activated kinases, SARK) (60). Studies showed that both phosphorylated serine 63 and 
serine 73 are required for coactivator CBP induced stimulation in vivo (33) and CBP 
binding in vitro (61). Serine 63 and serine 73 are located near a region in the N-terminus 
of c-Jun protein called the delta region which is believed to serve as a docking site for 
JNK (62) (Fig. 2). With delta region deleted, v-Jun does not bind to the JNKs/SARKs, 
and the serines in the protein corresponding to serine 63 and serine 73 are not 
phosphorylated (63). The mechanism of transactivation o f v-Jun remains elusive. It is 
suggested that JNK/SARK acts primarily as a positive regulator of c-Jun transactivation 
in situ, and that loss of the docking site for JNK/SARK physically uncouples v-Jun from 
this control (62).
In addition to the modulation of its activity by phosphorylation or redox, the Jun 
activity is also subject to regulation by a variety of protein-protein interactions with both 
bZIP and non leucine zipper proteins.
Recently, studies revealed that the activity of Jun proteins is also regulated by 
ubiquitin-dependent proteolytic process (64). Ubiquitin-dependent degradation is an 
important pathway of non-lysosomal protein breakdown. It is responsible for the 
removal of naturally short-lived, as well as aberrant, such as misfolded or damaged
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proteins. This process is mechanistically well understood. It involves the covalent 
attachment of ubiquitin, an evolutionary highly conserved 76-amino acid polypeptide 
which is abundantly present in all eukaryotic cells, to the e-amino group of one or more 
lysine side chains of target proteins. Consecutive rounds o f additional ubiquitination on 
previously attached ubiquitin moieties lead to the formation o f  branched protein species 
consisting of the substrate protein bearing multi-ubiquitin chains. Proteins that are 
modified in this manner are recognized by the proteasome, a large multi-catalytic protein 
complex that catalyzes the majority of protein breakdown in both the cytosol and the 
nucleus (65). At the proteasome the targeted protein is rapidly degraded in an ATP- 
dependent reaction. The selectivity o f ubiquitin-dependent protein degradation is 
conferred by specific interactions between cis-acting degradation signals on the substrate 
proteins and trans-acting factors of the ubiquitination machinery. Ubiquitination signals 
often consist of a recognition site and a ubiquitin attachment site (64). The relative short 
half-life of c-Jun, measured at 60 to 90 min in fibroblasts, was found to be, at least in 
part, mediated by ubiquitin-dependent protein degradation (66). The delta domain of c- 
Jun is essential for ubiquitination (66). C-Jun is targeted for ubiquitination by its 
association with inactive JNK through its docking site-delta domain-for JNK. 
Phosphorylation of c-Jun on Ser 73 by activated JNK protects c-Jun from ubiquitination, 
thus prolonging its half-life (67-69). V-Jun has a longer half-live than c-Jun (66). The 
27-amino acid delta domain that serves as a docking site for JNK is deleted in v-Jun, thus 
enabling v-Jun to escape regulation by degradation via the ubiquitin-proteasome pathway 
(64,66).
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Transforming activity o f  Jun
AP-1 transcription factors regulate many cellular processes in response to a 
variety of extracellular signals (for review, see (10-12,70)). There is ample evidence that 
the activity of AP-1 components, especially that of c-Jun, is essential for the proliferation 
and differentiation of some cell types. Recent studies suggested that Jun is also involved 
in induction of apoptosis (70). Addition of retinoic acid to non-differentiated F9 
embryonal carcinoma (EC) cells leads to induction of c-jun mRNA and triggers the 
differentiation of these cells into a primitive epithelial cell-type. Expression of both c-jun 
and c-fos is rapidly increased in many cell types in response to mitogens such as serum, 
EGF, TGFa, PDGF. Growth factors and cytokines (e.g., EGF, PDGF, TNFa, IL-1) exert 
their function by binding to specific cell surface receptors. Receptor binding triggers 
tightly coordinated multistep signal transduction cascades to the nucleus. In this cascade, 
nuclear transcription factors like c-Jun serve as terminal acceptors and convert these 
transient signals into long-term changes in gene expression. Such changes in cellular 
gene expression culminate in the initiation of DNA synthesis and eventually result in cell 
proliferation, differentiation or apoptosis. It is conceivable then that aberrant function of 
any component involved in these cascades may have dramatic consequences, leading to 
loss of growth control and neoplastic transformation.
Although the role of Jun proteins in transcriptional regulation has been 
extensively studied in recent years, the oncogenic properties of Jun are still poorly 
understood. Overexpression of v-Jun in CEFs results in strong oncogenic cell 
transformation and the transformed cells are tumorigenic when injected into birds 
(10,11). Overexpression of c-Jun is only weakly transforming in CEFs and the
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transformed CEFs are not tumorigenic (10,11). While overexpression of mammalian c- 
Jun is sufficient to induce neoplastic transformation in an immortalized line o f rat 
fibroblasts, Rat-la (71), transformation of primary cultures of rat embryo fibroblasts 
(REF) by c-Jun or v-Jun requires the cooperation with an activated Ha-ras (36,71).
The differences in oncogenic potential between v-Jun and c-Jun in CEF have been 
exploited extensively to elucidate the mechanisms by which v-Jun manifest its 
oncogenicity. A comparison o f the structure of v-Jun with its cellular counterpart, c-Jun, 
revealed a number of differences (Fig. 2). In the carboxyl-terminal DNA binding 
domain, v-Jun contains two non-conservative point mutations. In the amino-terminal half 
of v-Jun, a 27 amino acid region termed delta region was deleted. In addition, v-Jun also 
contains a tuncated long AU rich 3’ untranslated region (3). These structural differences 
are collectively responsible for the enhanced v-Jun oncogenicity (3).
Identification of chicken apolipoprotein A-I as a target of Jun regulation
Deregulation of a set o f crucial cellular genes has long been speculated as a cause 
of oncogenesis by v-Jun. Extensive efforts have been made to identify such genes.
Several target genes have been identified that are especially associated with the v-Jun 
induced transformation phenotype in avian fibroblasts, including JTAP-1 (72), bjk (73), 
and heparin-binding epidermal growth factor-like growth factor (74). JTAP-1, bjk, and 
heparin-binding epidermal growth factor-like growth factor are all upregulated in 
response to v-Jun overexpression in CEF.
In our laboratory, we have undertaken the objective o f identifying target genes 
that are associated with the v-Jun induced transformation phenotype. Using a subtractive 
hybridization approach to exploit the differences in oncogenic potential between v-Jun
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and c-Jun in CEF, we have identified a target gene, chicken apolipoprotein A-I (apoA-I), 
that appears to be specifically associated with v-Jun induced transformation in CEF (75).
We generated a subtractive cDNA library and identified a number of different 
clones. One o f the clones, JTAP-4, whose mRNA level was 5 to 10-times lower in v- 
Jun-transformed CEF as compared to that in RCAS vector infected CEF or c-Jun-infected 
CEF. After repeating Northern blot analysis on RNA isolated from more than five 
different sets of RCAS VJ-1 (v-Jun), RCAS CJ-3 (c-Jun) or RCAS vector infected CEF 
using the clone JTAP-4 as a probe, we confirmed that JTAP-4 was a negative target of v- 
Jun overexpression. Two independent JTAP-4 cDNA isolates were sequenced and the 
sequence information revealed that JTAP-4 is identical to the chicken apolipoprotein A-I 
(75). The chicken apoA-I gene transcription was repressed 5- to 10-fold in response to v- 
Jun overexpression (Fig. 3). Treatment with actinomycin D demonstrated that, although 
the overall levels o f apoA-I mRNA are lower in v-Jun-transformed CEF, the relative 
stability of the mRNA is identical to that in normal CEF. These results suggest that the 
decreased steady state apoA-I mRNA levels observed in Northern blot analysis is more 
likely due to a decrease in the apoA-I gene transcription (75). While overexpression of 
oncoproteins c/v-Myc and v-Src also resulted in reduction in the apoA-I mRNA levels, 
overexpression of other oncoproteins including c-Fos, v-Ha-Ras, c-Src and c-Ski either 
had no effect on the apoA-I expression or even resulted in a modest increase (75). These 
results indicate that repression of apoA-I gene expression is not strictly correlated with 
oncogenic transformation because overexpression of c-Fos, v-Ha-Ras also resulted in a 
transformed phenotype (75).
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FIG. 3. The chicken apoA-I gene is a negative target of v-Jun 
overexpression. Chicken embryo fibroblasts (CEF) were infected with either 
vector (R=RCAS)), RCAS CJ-3 (C=c-Jun), or RCAS VJ-1 (V=v-Jun). Total 
cellular RNA and proteins were isolated. (A). Immunoblot o f CEF infected 
with RCAS, RCAS CJ-3, or RCAS VJ-1 probed with an antibody against Jun 
(Oncogene Science AP-1 Ab-l). (B). Northern Blot o f the same infected CEF 
with the chicken apoA-I as a probe. Ethidium bromide stained ribosomal 
RNA is shown below the Northern Blot to demonstrate equal RNA loading 
(Hadman & Bos. (1998).Oncogene 16:655-660).
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Chicken apolipoprotein A-I: function and regulation
ApoA-I is the major protein constituent of serum high-density lipoprotein (HDL). 
HDL plays a major role in protection against atherosclerosis through its involvement in 
the reverse cholesterol transport mechanism in which cholesterol is transported from 
extrahepatic tissues to the liver for processing to bile salts (76-78). Plasma HDL levels 
are determined by the level of apoA-I gene transcription (79). In mammals, the apoA-I 
gene is predominantly expressed in the liver and intestine. Expression o f the mammalian 
apoA-I gene is regulated by the interplay of multiple transcription factors that bind to the 
apoA-I gene regulatory region. In human liver cells, expression o f the apoA-I gene is 
conferred by a hepatocyte-specific enhancer, located within nucleotides -220 to -110 
upstream of the apoA-I gene transcription start site (80). The enhancer activity depends 
on synergistic interaction between transcription factors bound to three distinctive sites 
within the enhancer: A (-214 to -192), B (-169 to -146), and C (-134 to - 1 19) (80,81) 
(see Fig. 4 and 5). Site A and C bind many members of nuclear receptor superfamilies 
including the liver-enriched hepatocyte nuclear factor 4 (HNF-4) (82-84), retinoid X 
receptor a  (85), and apolipoprotein A-I regulatory protein-1 (ARP-1) (86,87). Site B 
binds the hepatocyte-enriched factors HNF-3P (81,88) (see Fig. 4 and 5). Synergy 
between these factors during enhancer activation determines the tissue-specific apoA-I 
gene expression.
The apoA-I expression is regulated by various developmental, hormonal, dietary, 
pharmacological and physiological factors. Physical exercise (89-91), alcohol 
consumption (92), and being female (93) are well known factors that have a beneficial 
effect on the abundance of apoA-I protein. Pharmacological agents such as fibrates,
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phenytoin and phenobarbital also modulate the concentrations of this protein (94-96). A 
host of natural hormones, including thyroid hormones (87,97,98), glucocorticoid (99), 
sex steroids (100,101), and retinoic acids (102,103), were also reported to influence 
apoA-I transcription (see Fig. 5). In addition, we identified oncoprotein v-Jun as a factor 
that negatively regulates the apoA-I expression in CEF (75). Some factors, such as the 
orphan nuclear receptor ARP-1, a member o f nuclear receptor superfamily, regulate the 
apoA-I gene expression by binding to its promoter region directly. ARP-1 was shown to 
repress human apoA-I expression through binding directly to site A o f the apoA-I gene 
promoter region in human hepatoma HepG2 cells (82,87). Recent studies showed that 
transcription of the human and rat apoA-I genes declines with age (104). There were 
age-dependent changes of binding activity to two proximal sites, B and C. Decreased site 
B binding activity correlated with lower mRNA levels ecoding the activator, HNF-3p.
The age-dependent change in the pattern of binding to site C was due to a switch from the 
activator, HNF-4, to the repressor, ARP-1 (104). In both cases, ARP-1 regulates the 
apoA-I transcription by binding to the apoA-I promoter cis-elements directly. In addition 
to ARP-1, other members o f the nuclear receptor superfamily including thyroid receptors, 
retinoic acid receptor-a, and HNF-4, also bind to the apoA-I promoter directly (105,106).
Other factors modulate the apoA-I gene indirectly, such as the glucocorticoids 
(99,107). Glucocorticoids were shown to increase apoA-I gene expression in both in vivo 
and in vitro models (108). Recent studies showed that in the presence o f dexamethasone, 
the rat apoA-I promoter activity was stimulated three fold (99). Deletion o f site B (-170 
to -145) from the promoter completely abolished the stimulatory effects of 
glucocorticoids (99). But site B does not contain a consensus glucocorticoid receptor
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- 2 6 0  - 2 5 0  - 2 4 0  - 2 3 0  - 2 2 0
C h i c k e n  GGGGCCCCGGCCGGGCCGGAATTTGGGTCACCCGCAGCGTAAACATCTCC 
H um an GGGAGACCTGCAAGCCTGCAGACACTCCCCTCCCGCCCCCACfffiAACiCT
C h i c k e n
Hum an
site B
- 2 1 0  - 2 0 0  - 1 9 0  - 1 8 0  - 1 7 0
TCGGCCAACGCCGCATCCCCGGGGAGC-pTXTCTTTCnTGApGCTCTGCAA 
TGACCCCTGpCCTGCAGCCCCCGCAGCT rGCTGTTGTCCCA --jCTCTATTT~
C h i c k e n
Hum an
site C
- 1 6 0  - 1 5 0  - 1 4 0  - 1 3 0  - 1 2 0
AGCGGCGCTCCTTGGCCGGCTCTCCCGGGGCCGTGCGCAjlGATCC'i'TGAA 
gC TTJ-----------------------------------AGCCCCAGGGACAGAGC -  CGATCCTTGAA
- 1 1 0
CCAAT
- 1 0 0
C h i c k e n -ACGCG 1CACAT
Hum an CTC1 TAAGTT 1CACAT
- 9 0  - 8 0  - 7 0
IGCCCGCGCCGGGAGTG-ATTTCT-TGGGCTGCGGCG  
rGCCAGGACCAGTGAGC-AGCAAC-AGGGCC— GGGG
- 6 0  - 5 0  - 4 0  - 3 0 TATA
C h i c k e n  CTG-GCTTATC-------- TCCT-GCG— GGAACTGCCCCTCCTGtATAAATA
H um an CTGGGCTTATCAGCCTCCCAGCCCAGACCCTG-GCTGCAGA1ATAAATA
- 2 0  - 1 0  1 
C h i c k e n  GCGGCGGCGGGGAACCGCGGGCTCACACGGGACGAGCAGGTGCG 
H um an GGCCCTGCAAGAGCTGGCTGCTTAGAG
FIG. 4. Comparison o f the chicken apoA-I promoter region 
with that of the human apoA-I gene. Positions of site A, B, C, 
CCAAT box, and TATA box were boxed. The numbers above the 
sequences are corresponding to the chicken apoA-I promoter (Lamon- 
Fava., etal. (1992) J. Lipid Res. 33: 831-842).
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B TATA
+ Thyroid hormone T3 + Glucocorticoid + HNF-4 





FIG. 5. Schematic representation of the human apoA>I 
promoter. The cis-acting elements are shown by both geometric 
shapes and the most 5’ nucleotide for each site. List below each site 
(A, B, C, D, or TATA) indicates the hormones and transcription 
factors that act at these sites. The +/- signs indicate whether the 
hormones or transcription factors have a positive (+) or negative (-) 
effect on the site (Hargrove, et al., J. Mol. Endocrinology (1999) 22, 
103-111).
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motif and does not bind to bacterially expressed glucocorticoid receptor when used as a 
probe. However, the GR antagonist, RU486, completely blocks the increase in apoA-I 
mRNA levels following treatment with dexamethasone (107). These results suggest that 
GR acts via an indirect mechanism (99). Such a mechanism could involve GR activation 
of a factor that, in turn, binds to site B. Studies have demonstrated that HNF-3P binds to 
the site B in human apoA-I gene promoter and increases transcription of the gene (81,88), 
and that glucocorticoids induce site B binding activities (99). It is possible then that the 
stimulatory effect of glucocorticoids on expression of the apoA-I gene may act through 
increased abundance or activity of HNF-3p.
Similarly, sex steroid estrogen also stimulates the apoA-I transcription through an 
indirect mechanism (109). The actions o f the hormone on the apoA-I gene transcription 
involve estrogen receptor, but the apoA-I gene promoter does not contain a binding motif 
for the nuclear estrogen receptor. Studies showed that estradiol potentiates the 
synergistic interactions between two transcription factors, HNF-4 and HNF-3P that bind 
to the cis-acting elements in the apoA-I promoter, site A and site B (81,88,110). The 
synergism between HNF-4 and HNF-3p is believed to be mediated by factor (s) that 
influence protein-protein interactions between these two proteins. Co-repressor, RIP 140, 
is thought to be such a factor, and the activity of this factor is modulated by estradiol 
(101). It is suggested that estrcdiol-activated endoplasmic reticulum somehow sequesters 
RIP 140 protein, leading to the relief of repression and thus increased levels o f apoA-I 
gene transcription. Another sex hormone, androgen, acts in a fashion opposite to that of 
estrogen. Studies suggest that androgens act by antagonizing the actions o f estrogen, and 
that androgens have no direct effect on the apoA-I transcription (111).
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The pattern o f tissue expression o f the apoA-I gene in avian species is very 
different from that in mammals. Although the liver and the intestine are major sites of 
chicken apoA-I mRNA synthesis, apoA-I gene expression also occurs in most other 
chicken tissues (112-117). The chicken apoA-I gene spans 1.5 kb and contains 4 exons 
and 3 introns, closely resembling the mammalian gene (118,119). While certain 
sequences in the 5’ upstream region o f chicken apoA-I gene are highly homologous to the 
mammalian gene site C and the 5’ half of site B, the chicken gene lacks sequences 
corresponding to the mammalian gene site A and the remaining 3’half o f site B (Fig. 4).
Most apolipoproteins have originated from duplication of an ancestor 
apolipoprotein gene and subsequent modification of the duplicated copy. ApoA-I, C-III, 
and A-IV genes are closely arranged in a gene cluster in both birds and mammals. It is 
possible that the sites A, B, and C organization of the human apoA-I gene promoter may 
have arisen during evolution as the duplication of the half site B and site C, which is still 
the structure of the chicken gene (120,121). The broader tissue expression o f the chicken 
apoA-I also resembles that of mammalian apoE, which is absent in avian species. It has 
been suggested that, in birds, apoA-I may be the functional homologue o f mammalian 
apoE ( 122). Mammalian apoE also plays an important role in cholesterol transport. In 
addition, recent studies have shown that mammalian apoE plays a critical role in 
neurobiology. The apoE4 allele is the major susceptibility gene related to the occurrence 
and early age of onset of Alzheimer’s disease (123). Finally, unlike human apoA-I, 
which aggregates in the absence of lipid, chicken apoA-I is monomeric in the lipid-free 
state (124). This physical characteristic makes chicken apoA-I a good model to further 
characterize the apoA-I protein and to study the mechanism by which it functions in
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cholesterol transport. In recent years, extensive studies have been done to define the cis- 
and trans-acting factors involved in regulation of hepatocyte and intestinal specific 
expression of the mammalian apoA-I gene, but little is known regarding the factors and 
cis-acting elements that regulate the chicken apoA-I gene expression. Our preliminary 
studies suggest that v-Jun may play an important negative regulatory role in regulation of 
the chicken apoA-I gene expression.
SIGNIFICANCE
Atherosclerotic cardiovascular disease is the leading cause of death in industrial 
societies. The important role of high-density lipoprotein (HDL) and its major protein 
component, apolipoprotein A-I (apoA-I), as being anti-atherogenic has been well 
established. There is sufficient evidence to support a causal association between plasma 
HDL levels and the subsequent development of coronary heart disease. The observation 
that plasma HDL levels are directly correlated with the liver apoA-I mRNA levels 
suggests that factors affecting apoA-I gene expression play an important role in 
atherosclerosis susceptibility. Recent studies in transgenic mice and rabbits for human 
apoA-I showed that overexpression of the apoA-I protein increases serum HDL 
cholesterol concentration and reduces high-cholesterol-diet-induced atherogenesis (125). 
The results suggest that up-regulation of apoA-I synthesis may afford a new approach for 
the prevention or therapy of atherosclerotic disease. The understanding of how the 
chicken apoA-I gene is regulated in CEF and the differences in regulation between 
mammalian and avian species regarding the differential expression of the apoA-I gene is 
valuable in developing strategies to increase human apoA-I gene expression.
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Derangement of cholesterol homeostasis and apolipoprotein synthesis has been 
associated with certain types of cancer. Correlative reports have identified decreased 
levels of HDL in patients suffering from acute lymphocytic leukemia (ALL) (126,127). 
HDL levels were restored to normal levels with successful chemotherapy.
Apolipoprotein D (Apo D) is a protein component of the human plasma lipid transport 
system which is present in benign and malignant human breast tissues. It was reported 
that expression of the apoD is elevated in the breast cancer specimens (128). Studies 
have shown that there was a positive association of Apo D content in male breast tumors 
with favorable outcome and that apo D expression was a significant independent 
indicator of relapse-free survival in male breast cancer (129). Recent studies suggest a 
possible relationship of the apoE4 gene to both breast cancer and prostate cancer 
(130,131). It is thought that apoE4 keeps serum triglycerides elevated by reducing their 
clearance and that triglycerides themselves appear to be a risk factor for breast cancer 
(130). A link between atherosclerosis and tumor angiogenesis involving apolipoprotein 
(a) was also suggested (132). In addition, the elevated apoA-I mRNA levels were used to 
detect homogenous colon cancer dissemination in a clinical study and was found to be 
highly specific and sensitive (133). It appears that deregulation o f apolipoprotein 
expression may be a consequence o f certain types of oncogenic activity.
SPECIFIC AIMS
We have identified v-Jun as one of the factors that affect chicken apoA-I gene 
expression. Overexpression of oncoprotein v-Jun in CEF represses chicken apoA-I 
mRNA level by 10-fold. The decrease of apoA-I steady state mRNA level is due to a 
decrease at the transcriptional level (75).
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During the process o f initial deletion analysis, we also observed consistently 
elevated CAT activity in the plasmid containing -6800 bp upstream of the apoA-I 
transcription start site, but not in the plasmid containing -6000 bp upstream of the 
transcription start site. We speculated that there is an enhancer located within the 800 bp 
DNA fragment spanning from -6800 bp to -6000 bp upstream o f the apoA-I transcription 
start site.
The overall objective of this study is to provide some insight into the 
underlying mechanisms by which the apoA-I gene transcription is regulated, 
especially by the v-Jun oncoprotein.
Aim 1: To map the cis-acting elements in the chicken apo A -I promoter region that 
mediate the repressor activity o f  v-Jun
Regulation of gene expression depends on binding o f transcription factors to gene 
promoter elements. The v-Jun oncoprotein regulates target gene expression through both 
direct DNA binding and through transcription factor “cross-talk”. As a first step to 
understanding the underlying mechanism by which apoA-I gene expression is repressed 
by v-Jun, the cis-acting elements in the apo A-I promoter region that mediate the repressor 
activity of v-Jun were mapped.
Aim 2: To determine i f  v-Jun represses the apoA-I gene transcription through binding 
to the apo A-1 promoter directly
As a transcription factor, v-Jun can regulate target gene expression either directly 
by binding to DNA or indirectly by protein-protein interactions. To distinguish between 
these possibilities, a series o f gel shift assays and supershift assays were performed.
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Aim 3: To determine the biochemical domains o f v-Jun required fo r  the repression o f  
the apo A-I gene expression
V-Jun has three well-characterized functional domains: basic DNA binding, 
leucine zipper dimerization, and transactivation. How each domain contributes to 
repression of the apoA-I gene was assessed by a structure-and-function approach.
Aim 4: To characterize an enhancer element in the chicken apo A-I gene S ’-flanking 
region
An 800-bp enhancer located within nucleotides -6800 bp to -6000 bp upstream of 
the apo A-I gene transcription start site was identified. The functional properties and 
species specificity o f the enhancer were investigated. The cis-acting elements within the 
enhancer that mediates binding of nuclear factors were characterized.
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CHAPTER II 
MATERIALS AND METHODS 
CELL CULTURE AND TRANSFECTIONS
Culture of primary CEF was performed on 10-day-old embryo as previously 
described (3). In subsequent passages, CEFs were maintained in cloning media IX F10 
(GIBCO) containing 4% deactivated chicken serum (GIBCO), 10% donor calf serum 
(Atlantic Biological), 1% L-glutamine, 1% penicillin/streptomycin, 1% MEM vitamin 
solution (all from GIBCO) and 0.4% DMSO (Sigma). Hep G2 cells, NIH3T3 cells and 
MCF7 cells were grown in MEM culture medium supplemented with 10% fetal bovine 
serum (Atlantic Biological).
For CEFs that were infected with RCAS vector, RCAS VJ-1 or RCAS v-Jun 
mutants retroviruses, transient transfections were carried out by the DMSO shock method 
described in (3). Cells were seeded at a density of 3.0X106 in 100-mm plates 24 hours 
prior to transfection. Five micrograms of plasmid DNA was used. Half microgram of 
CMV-f)-galactosidase was cotransfected in some experiments as an internal transfection 
efficiency control. Cells were harvested 96 hours later and cellular proteins were 
extracted using three cycles of freeze-thaw at -70°C and 37°C, respectively. Protein 
assays were performed using Bio-Rad method (75). Two hundred to six-hundred 
micrograms of protein were used in CAT assays.
For CEFs that are used for the enhancer identification and characterization, 
transient transfections were carried out by FuGene 6 method (Roche) according to 
manufacturer’s instructions. Cells were seeded at a density of 4.0X105 to 5.0X105 in 2- 
mm 6-well plates 24 hours prior to transfection. 2.5 pg to 2.9 pg of plasmid DNA were
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used along with 0.5 ug to O.lug CMV-|3-galactosidase as an internal transfection 
efficiency control. Cells were harvested 48 hours later and cellular protein was extracted 
using three cycles of freeze-thaw at —70°C and 37°C, respectively. Protein assays were 
performed using Bio-Rad method (75). 50ug to lOOug of protein were used in CAT
assays.
PLASMIDS CONSTRUCTIONS
The constructions o f RCAS VJ-1, RCAS VJ-3, RCAS VJSNco, and RCAS 
VJGLZ have been described previously (3,134). The constructions of RCAS VJ/C/EBP 
and RCAS VJGLZ/C/EBP are described (Bos, et al., in press). Plasmids, p- 
6800/+1.CAT, p-311/19.CAT, and p-60/19.CAT, consist of nucleotides -6800 to +1, -  
311 to +19, and -60 to +19, respectively, of the chicken apo A-I gene 5’-flanking region 
fused to a chloramphenicol acetyltransferase (CAT) gene were reported previously (75). 
Plasmid p-194/19.CAT was made using a PCR amplified product obtained with forward 
primer: CGGGGACGTCCTGTTTGCTGAGG (the apoA-I promoter-194 to -172), 
reverse primer: CACTGCTCGTCCCGTGTG (positions +19 to +2). Plasmid p- 
311/263.CAT was used as template. The PCR product was first cloned into pGEM-T 
(Promega) and then was cut with Spe I, blunt-ended with Klenow, cut again with Not I. 
The final product was gel-purified and cloned into pCAT/Blue cut with Hind III, blunt- 
ended with Klenow and then cut with Not I. The apoA-I promoter CAT plasmids with 
the 800 bp homologous enhancer p(-6800 to -6000)-311/19.CAT, p(-6800 to -6000)- 
194/19.CAT and p(-6800 to -6000)-60/19.CAT were constructed by first digesting the 
coresponding plasmids p-311/19.CAT, p-194/19.CAT, and p-60/19.CAT with Asp718 
and Not I. The Asp 718-Not I DNA fragments containing the apoA-I promoter regions
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and the CAT gene were ligated with Bam HI-Not I fragment containing the 800 bp 
enhancer from p-6800/+l.CAT (75).
All the plasmids used to identify and characterize the enhancer were generated by 
blunt-end ligation to obtain the constructs containing inserts in both orientations. To 
construct p (-6800 to -6010)-311/19.CAT, 800-bp Asp718 and BamHI fragment was 
excised from p-6800/+l.CAT, blunt-ended with Klenow (Promega) and inserted 
upstream in both orientations into p-311/19.CAT digested with Asp718. To construct p 
(-6800 to -6000) Bluescript SK (+), the same 800-bp fragment was inserted into 
pBluescript SK (+) (Stratagene) digested with Asp718 and BamHI. This 800-bp Asp718 
and BamH I fragment of plasmid -6800/+1.CAT was also used as an intermediary step to 
generate most of the 5’- and 3- deletions of the full length enhancer. To construct 
plasmids p (-6800 to -6135)-311/19.CAT and p (-6135 to -6010)-311/19.CAT, the 800- 
bp fragment was digested with HinF I, blunt-ended with Promega Klenow and the 
resulting two fragments (669-bp and 128-bp long) were inserted upstream in both 
orientations into p-311/19.CAT. To construct plasmids p (-6800 to -6428)-311/19.CAT 
and p (-6428 to -6010).CAT, the blunt-ended 800-bp fragment was digested with Sac I, 
3’-blunt-ended with Klenow and the resulting two fragments (550-bp and 241-bp long) 
were inserted upstream in both orientations into p-311/19.CAT. To construct plasmids p 
(-6800 to -6557)-311/19.CAT and p (-6557 to -6406)-311/19.CAT, the 800-bp fragment 
was digested with Ban I and Ava I, blunt-ended with Klenow, and the resulting two 
fragments (247-bp and 155-bp long, respectively) were inserted upstream in both 
orientations into p-311/19.CAT. To construct plasmids p (-6800 to -6629)-311/19.CAT 
and p (-6629 to -6010)-311/19.CAT, the blunt-ended 800-bp fragment was digested with
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Pvu II and the resulting two fragments (171-bp and 620-bp long) were inserted upstream 
in both orientations into p-311/19.CAT. To construct plasmid p (-6629 to-6406)- 
311/19.CAT, the 800-bp fragment was digested with Pvu II and Ava I, the resulting 223- 
bp fragment was then blunt-ended and inserted upstream in both orientations into p- 
311/19.CAT. Plasmid p (-6800 to -6406)-311/19.CAT was constructed by digesting p- 
6800/+1.CAT with Asp718 and Ava I, the 395-bp fragment was blunt-ended and then 
inserted upstream in both orientations into p-311/19.CAT. Plasmid p (-6406 to -6010)- 
311/19.CAT was constructed by digesting plasmid -6800/+1.CAT with Ava I and BamH 
I and the resulting 396-bp fragment was blunt-ended and inserted upstream in both 
orientations into p-311/19.CAT.
To generate plasmids p (-6800 to -6010) CAT-Promoter, the 800-bp Asp718- 
BamH I fragment excised from p (-6800 to -6010) Bluescript was blunt-ended and 
inserted downstream of the SV40 promoter in both orientations into pCAT-Promoter 
(Promega) digested with Bam H I and blunt-ended. To generate plasmid p (-6800 to -  
6010) SV2CAT, plasmid p-6800/+1 .C AT was first digested with BamH I, blunt-ended. 
and then was digested with Xho I, the resulting 800-bp fragment was inserted upstream in 
forward orientation into pSV2CAT (135,136) that was digested with Sal I first, blunt- 
ended, and then digested with Xho I.
Plasmid containing the human apoA-I promoter 1.3kb (positions -1064 to +234), 
p 1.3kbhAI.CAT, was first constructed by PCR and served as an intermediate plasmid for 
subsequent construction of plasmids containing human apoA-I minimal promoter with or 
without the 800-bp enhancer sequences. To construct plasmid pl.3kbhAI.CAT, genomic 
DNA was extracted from human breast cancer MCF7 cells and lOOng was used as
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
32
template in PCR reaction to amplify 1.3-kb fragment using primers corresponding to -  
1064 to -1042 (forward: gatggtgctcaaacaccaacgg) and +234 to +215 (reverse: 
ctgaagggccgtgggggacc). The resulting 1.3-kb PCR products were eluted out o f a low 
melting agarose gel and ligated into vector pGEM-Teasy (Promega). The 1.3-kb 
fragment was excised from pGEM-Teasy with EcoR I digestion, blunt-ended with 
Klenow and then subcloned into vector pCAT-Basic (Promega) which was digested with 
Xba I, blunt-ended with Klenow and dephosphorylated with calf intestinal alkaline 
phosphatase (GIBCO). To construct plasmid containing human apoA-I minimal 
promoter, p-41/234hAI.CAT-Basic, pl.3kbhAI.CAT-Basic was digested with Pst I and 
the 4.6-kb DNA fragment containing the vector pCAT-Basic and human apo A-I minimal 
promoter (positions -41 to +234) was excised and self-ligated. Plasmid, p (-6800 to -  
6000)-41/234hAI.CAT-Basic was constructed by inserting the 800-bp fragment excised 
from p (-6800 to -6000) Bluescript SK (+) with Asp7l8 and BamH I digestion and blunt- 
ended with Klenow downstream in both orientations into the vector p-41/234hAI.CAT- 
Basic digested with Hind III, blunt-ended with Klenow and dephosphorylated with calf 
intestinal phosphatase. Some o f the constructs were confirmed by sequencing and all the 
constructs were confirmed by restriction enzyme digestions.
PREPARATION OF NUCLEAR EXTRACT FROM CEF
Crude nuclear extract was isolated from chicken embryo fibroblasts as described 
(134). Briefly, cells were collected, incubated in hypotonic solution buffer A (lOmM 
HEPES, pH 7.9, 1.5mM MgCl2, 10mM KC1, 0.5% CA-630, 0.5mM DTT, ImM PMSF, 
2ug/ml Aprotinin, 0.5ug/ml Leupeptin and lug/ml Pepstatin) at 4°C for 10 min, mixing 
gently every minute. Nuclei were sedimented at l,000x g for 10 min, resuspended in
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extraction buffer, buffer C (20mM HEPES, pH 7.9, 25% Glycerol, 0.42M NaCl, 1.5mM 
MgCb. 0.2mM EDTA, ImM PMSF, 0.5mM DTT, lug/ml Aprotinin, 0.5ug/ml 
Leupeptin, and lug/ml Pepstatin) at 4°C for 30 min with gentle mixing. Insoluble debris 
was removed by centrifugation at 4°C at 10,000 x g for 30 min. The supernatant was 
dialyzed against buffer D (20mM HEPES, pH 7.9, 20% Glycerol, 0.1M KC1, 0.2mM 
EDTA, 0.5mM PMSF, and 0.5mM DTT) at 4°C for 4 hours with one change at 2 hours. 
Samples were stored at -70°C in 30ul aliquots. Protein concentration was determined by 
the Bio-Rad method (75).
SYNTHESIS OF OLIGONUCLEOTIDES
The oligonucleotides that are labeled as probes were all synthesized commercially 
(GIBCO).). All of the oligonucleotide sequences described all from 5 ’ to 3 ’. Six pairs 
of oligonucleotides were synthesized to assemble the 332-bp apoA-I promoter region. 
Oligonucleotides -311 to -244, forward: ggtaccaacccggcgcccgggctctgcgccaatcccc 
gggggctgcga, reverse: tccggcccggccggggcccctcgcagccccggggattggcgcagagc. 
Oligonucleotides-251 to —192, forward: gggccggaatttgggtcacccgcagcgtaaacatctcctc; 
reverse: ccggggatgcggcgttggccgaggagatgtttacgctgcg. Oligonucleotides -211 to -142, 
forward: ggccaacgccgcatccccggggagctcctgtttgctgaggctgaggctctgcaaag; reverse: 
gagccggccaaggagcgccgctttgcagagcctcagcaaacaggagctcc. Oligonucleotides -156 to -85, 
forward: ggctctcccggggccgtgcgcacgatccttgaactctacgcgccacatcg; reverse: 
tcccggcgcgggcgatgtggcgcgtagagttcaaggatcgtgcgcac. Oligonucleotides -91 to -26, 
forward: gccgggagtgatttcttgggctgcggcgctggcttatctcctgcgggaac; reverse: 
tgcaggaggggcagttcccgcaggagataagccagcgccgcag. Oligonucleotides —41 to +21, forward:




Four pairs of oligonucleotides were selectively synthesized from the apoA-I 
enhancer. Oligo I, forward: gtgatgtcagggacgagtctctggaaagca (positions -6150 to -6121), 
reverse: gggagctggcaagatgcgtgctttccagag (positions -6103 to -6132). Oligo II, forward: 
ggtatgaccaggacacgtttgggttttggt (positions -6178 to -6149), reverse: 
ctcgtccctgacatcaccaaaacccaaacg (positions -6135 to -6164). Oligo III, forward: 
tggaagggccccgaggctgcgtgggcggcc (positions -6416 to -6387), reverse: 
aggcggtgctggcagtgcagggccgcccac (positions -6367 to -6396). Oligo IV, forward: 
ctggctgccggagtggggcaggggcaaggg (positions -6506 to -6477), reverse: 
gcccagagcgcaggctgcttcccttgccccc (positions -6457 to -6493). C/EBP, HNF-3, SP-1, 
HNF-4 and AP-1 specific oligos are listed in Table II.
GEL MOBILITY SHIFT ASSAYS
Overlapping single-stranded oligonucleotides were annealed at 48°C for 10 min 
and allowed to cool gradually to room temperature. The resulting double-stranded 
oligonucleotides were labeled by fill-in with Klenow DNA polymerase I incorporating 
the appropriate [a-32P]dNTPs. The probe -311 to +21 of the apoA-I promoter region 
was PCR-generated and cloned into pGEM-T vector (Promega), subsequently excised, 
gel-purified, and 5’-end labeled with [a-32P]dNTPs. Gel mobility shift assays were 
performed as previously described (134) with modifications. Briefly, 16 pg of nuclear 
extract were preincubated in the binding buffer (20mM HEPES, pH 8.0, 35% glycerol, 
0.2mM EDTA, 40mM NaCl, 8mM MgCh, 40mMDTT, 4mM spermidine) with 1 pg non­
specific competitor poly(dl-dC) on ice for 15 min. The reaction mixture was then
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incubated with l|al o f 32P-labeled probe for 15 min on ice. Competitors were added with 
probes in competition gel shift assays. Samples were run on 6% acrylamide gels at 25 
mA for 2 to 3 h. Gels were dried and exposed to x-ray films (FUJI). Fifty to one- 
hundred-fold excess of unlabeled oligonucleotides was added as competitor. The 
following antibodies were used in supershift assays: Ab-1, rabbit polyclonal antibody 
raised against c-Jun DNA binding domain residues 247 to 263 (Santa Cruz); Ab-2, rabbit 
polyclonal antibody raised against c-Jun DNA binding domain residues 209 to 225 
(Oncogene); Ab-3, rabbit polyclonal antibody raised against c-Jun amino terminal 
domain residues 91 to 105 (Santa Cruz). The antibodies were either added 30 min before 
the probe or added after the probe for 30 min on ice.
SEQUENCING
Sequence analysis of the 800-bp fragment was obtained using an automatic 
sequencer (PharmaciaLKB. A.L.F.). The sequencing reactions were performed using the 
AutoRead™Kit (Pharmacia) according to the manufacturer’s instructions. Five 
micrograms of plasmid p (-6800 to -6000) Bluescript SK (+) were used as template.




MAPPING OF THE V-JUN RESPONSIVE ELEMENTS IN THE APOA-I 
PROMOTER REGION
The role o f v-Jun in transcriptional regulation has been extensively examined in 
recent years. First, Jun can recognize and bind to specific DNA sequences, such as AP-1- 
or CRE-like elements. Once bound, Jun can regulate target gene expression from nearby 
promoters through complex formation with its many dimerization partners. Second, Jun 
proteins can regulate, positively or negatively, many target genes that do not contain AP- 
1- or CRE-like sites in their promoter region through protein-protein interaction with 
non-leucine zipper transcription factors. Repression of target gene expression in response 
to v-Jun overexpression can be mediated by several molecular mechanisms (Fig. 6). The 
simplest mechanism involves competition for a common DNA binding site, for instance, 
v-Jun may exclude the binding of an activator by virtue o f recognizing the same, 
overlapping, or adjacent binding site. This passive repression may be augmented by 
active repression once v-Jun is promoter bound (Fig. 6a). Yet, based on published 
sequence information (118,119), there is no consensus AP-1 site within the chicken 
promoter region. Therefore, if v-Jun binds to the apoA-I promoter directly, it would 
recognize a fairly divergent AP-1 or CREB-like site. A second mechanism involves 
protein-protein interactions. V-Jun may repress either basal or activated transcription by 
competing for binding o f activators or competing with an activator for a limiting common 
coregulator or general transcription factor (Fig. 6b and 6c). This would result in 
depleting of these factors, a phenomenon called squelching. A third mechanism involves
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promoter modification (Fig. 6d). For example, overexpression o f v-Jun may upregulate 
methyltransferase resulting in methylation of the apoA-I promoter, which is extremely 
GC rich. CpG methylation has long been associated with repressed gene transcription 
(137-141). A fourth mechanism involves secondary gene expression regulation (see Fig. 
6e and 6f). V-Jun may repress target gene expression by either upreguiating a repressor 
or downregulating an activator. A fifth mechanism may involve reduction of 
transactivation potential of an activator by v-Jun. These mechanisms are not exclusive. 
V-Jun may employ more than one mechanism to repress target gene transcription.
A large part of gene regulation is governed by sequence-specific transcription 
factors, which bind to cis-acting elements located within the promoter region of 
responsive genes. As a first step to investigate the molecular mechanism by which Jun 
functions as a repressor on apoA-I gene expression, the cis-acting element (s) in the 
apoA-I promoter region that mediate the repression by v-Jun were mapped.
Initial deletion analysis
We have shown previously that overexpression of v-Jun in CEFs represses apoA-I 
gene transcription (Fig. 3) (75). To determine whether v-Jun regulates apoA-I at the level 
of promoter activity, a genomic clone o f apoA-I from a chicken EMBL3 genomic library 
(Clontech) was isolated. A genomic DNA fragment that extends to -6800 bp has been 
fused to the gene for chloramphenicol acetyltransferase (CAT), and its activity has been 
assayed in CEF overexpressing v-Jun, or RCAS vector alone. Activity o f the promoter- 
reporter construct decreased 10-fold in CEF overexpressing v-Jun as compared to that in 
control CEF infected with RCAS vector alone (Fig. 8, lane 1, both panels). In initial 
studies to map the negative regulatory element(s) responsive to v-Jun, a series o f 5’-




























FIG. 6. Possible mechanisms for repression of chicken 
apoA-I transcription by v-Jun. (a) Passive repression by competing 
for the apoA-I activator binding site, (b) Active repression of basal 
transcription, (c) Squelching of transactivator of apoA-I 
transcription, (d) Secondary gene regulation-repression o f apoA-I 
transcription, (e) Secondary gene regulation-activation o f apoA-I 
repressor expression. (0  Secondary gene regulation-modification of 
the apoA-I promoter. GTFs, general transcription factors.
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deletion mutations o f the chicken apoA-I gene fused to the CAT gene were generated, 
and the resulting plasmids were transiently transfected into CEF either infected with 
RCAS VJ-1 or RCAS vector alone (Fig. 7 and 8). Repression o f the apoA-I promoter 
activity by v-Jun was determined by measuring the reporter gene CAT activities. The 
CAT activities of the plasmids containing -6000 bp to —311 bp upstream of the apoA-I 
gene transcription start site were at or below basal level even in control CEF infected 
with RCAS vector alone, suggesting that the apoA-I promoter is subject to complex 
positive and negative regulatory controls. Deletion to - 3 11 bp upstream of the apoA-I 
transcription start site resulted in the reappearance of promoter activity in control CEF, 
but the promoter activity decreased dramatically in CEF infected with RCAS VJ-1 (Fig.
8, lane 6, both panels). Taken together, these results indicate that the v-Jun responsive 
element (s) is located within nucleotides -311 to +19 upstream o f the apoA-I gene 
transcription start site.
Further mapping of the v-Jun responsive elements in the apoA-I promoter region
Initial deletion analysis located the v-Jun responsive elements in the chicken 
apoA-I promoter within nucleotides -311 to +19 upstream of the apoA-I gene 
transcription start site. Further deletion to -193 and -60 (Fig. 9 and Fig. 10, lane 1, 2, 3) 
resulted in almost total loss o f promoter activity even in RCAS infected CEF. Because 
promoter activation was weak, it was difficult to determine any inhibitory effect by v- 
Jun. For this reason, a strategy to increase apoA-I promoter activity was developed.
During the process of the initial deletion analysis, we observed consistently 
elevated CAT activity in the plasmid containing -6800 bp upstream o f the apoA-I 
transcription start site, but not in the plasmid containing -6000 bp upstream o f the gene
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The chicken apoA-I gene 5’-flanking region
-6800
-6000
FIG. 7. Schematic representation of 5’-deletion 
mutations of the apoA-I promoter-reporter constructs. A
series o f 5 ’-deletions of the apoA-I promoter spanning from -6800 
to -311 nucleic acids upstream of the gene transcription start site 
were fused to the chloramphenicol acetyltransferase (CAT) gene.
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FIG. 8. Initial deletion analysis of the apoA-I promoter activity 
in response to infection with RCAS vector, or RCAS VJ-1 (v-Jun). A
series of 5’-deletions o f  the apoA-I promoter were fused to the CAT gene 
and were transiently transfected into CEF either infected with RCAS 
vector or RCAS VJ-1. The cells were harvested 96 hours later and CAT 
activities were measured to determine the apoA-I promoter activity. 
Percent acetylation is shown numerically above each lane. Lane 1, -6800 
CAT; lane 2, -6000 CAT; lane 3, -5000 CAT; lane 4, -3300 CAT; lane 5, - 
2500 CAT; lane 6, -311 CAT.
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transcription site (Fig. 8). We speculated that there is an enhancer located within the 800 
bp DNA fragment spanning from -6800 bp to -6000 bp upstream of the gene 
transcription start site.
This enhancer was inserted upstream in the forward orientation into three 
plasmids containing various 5’-deletions of the apoA-I promoter fused to the CAT gene 
(Fig. 9). The resulting plasmids were transiently transfected into CEFs either infected 
with retroviral vector RCAS or with RCAS VJ-1. The promoter activity was determined 
by measuring CAT reporter activity. Figure 9 shows the schematic representations o f the 
apoA-I promoter reporter constructs used in transient transfection experiments. Insertion 
of the 800-bp homologous enhancer increased the activity o f all three apoA-I promoter- 
reporters dramatically compared to the corresponding ones without the homologous 
enhancer (Fig. 10 and 11). Consistent with our previous results, the activated 
tmascriptional activity of the construct containing the 330-bp apoA-I promoter region 
(positions -311 to +19) is much higher than that of the constructs with further 5’- 
deletions (positions —193 to +19 and -60 to +19 respectively), suggesting the presence of 
a strong activating sequence within the -311 to -193 promoter region (Fig. 10, RCAS 
panel, lane 5, 6, 7). Repression of apoA-I promoter activity by v-Jun was observed in all 
the apoA-I promoter reporters containing nucleotides -311 to +19, -193 to +19 and -60 
to +19 respectively (Fig. 10 and 11), suggesting that the v-Jun responsive element may 
lie within the first 60 nucleotides. However, the decrease in promoter activity is much 
more pronounced in the construct containing the -311 to +19 promoter region (Fig. 11, 
lane 5, 6, 7). Deletion of the promoter from -311 to -193 reduced the magnitude of 
decrease in promoter activity, suggesting that the strong activating sequence located















FIG. 9. Further mapping of v-Jun responsive elements in the 
apoA-I promoter region — schematic representation of 5’-deletion 
mutations of the apoA-I promoter-reporter constructs with the 
enhancer element. The 800-bp enhancer element was inserted upstream in 
a forward orientation into three 5’-deIetions of the chicken apoA-I 
promoter-reporter plasmids. An internal deletion construct was made with 
nucleotides -3 11 to -60 of the apoA-I promoter region deleted.
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FIG. 10. Further mapping of v-Jun responsive elements in 
the apoA-I promoter region — autoradiograph of CAT assay of 
apoA-I promoter activity. 5 ug of the apoA-I promoter-reporter 
constructs without or with the enhancer element and the internal 
deletion constructs were transiently transfected into CEF either infected 
with RCAS vector (RCAS) or RCAS VJ-l (v-Jun). The infected cells 
were harvested 96 hours later and CAT activity was assayed. 1. p-311. 
CAT; 2. p-193. CAT; 3. p-60. CAT; 4. p (-6800 to - 3 1 1)-60.CAT; 5. p 
(-6800 to -6000)-31 l.CAT; 6. p (-6800 to -6000)-193.CAT; 7. p (- 
6800 to -60001 -60.CAT.
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v-Jun
FIG. 11. Further mapping of v-Jun responsive elements in 
the apoA-I promoter region -  quantitation of apoA-I promoter 
activity in CEF in response to infection of RCAS vector or RCAS
V-l. 5 fig of a series of 5’-deIetions of apoA-I promoter-reporter 
constructs without or with the 800-bp homologous enhancer and an 
internal deletion plasmid were transiently tranfected into CEF either 
infected with RCAS vector (RCAS) or RCAS VJ-1 (v-Jun). The 
infected cells were harvested 96 hours later and CAT activity was 
examined. 1 fig of CMV-(J-Galactosidase was cotransfected with the 
apoA-I promoter-reporter constructs in some experiments as internal 
transfection efficiency control. Results are represented as percentage 
of CAT acetylation. Data represents the average of at least three 
independent transfection experiments. Lanes are the same as that in the 
legends of Figure 10.
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within the -311 to —193 promoter region might be involved in mediating apoA-I 
transcriptional repression by v-Jun as well. We reasoned that if the v-Jun responsive 
element lies within the first 60 nucleotides, deletion of the -311 to -60  promoter region 
would not affect decrease in promoter activity; otherwise, if the v-Jun responsive element 
lies somewhere within the -311 to -60  promoter region, deletion of this fragment would 
abolish v-Jun responsiveness of the promoter. To that end, an internal deletion was 
made. This internal deletion contains -6800-bp 5’-flanking region of the apoA-I with the 
promoter region -311 to -60 deleted. Deletion of nucleotides within —311 to -60 of the 
apoA-I promoter reduced promoter activity to below basal level, and no repression by v- 
Jun could be observed (Fig. 10, lane 4 in both panels).
Even though both CEF infected with vector and CEF infected with RCAS VJ-1 
come from the same source of primary CEF, they were maintained separately after 
retroviral infection. The long infection cycle lasts for 10 to 14 days. It might be possible 
that v-Jun-induced transformation in CEF affects the ability o f these cells to take up 
plasmid DNA in transient transfection assays. To determine whether transient 
transfection efficiency in CEF infected with vector is the same as that in CEF infected 
with RCAS VJ-1, plasmid CMV-P-Galactocidase was used to cotransfect CEFs along 
with the apoA-I promoter reporter constructs as an internal transfection efficiency 
control. Meanwhile, P-Gal staining experiments were also performed in control CEF 
infected with RCAS vector and CEF infected with RCAS VJ-l. Results from P- 
Galactosidase assays demonstrated that P-Galactosidase activity is similar in both control 
CEF and CEF overexpressing v-Jun. In addition, P-Gal staining results shown in Figure 
12 indicate that there are similar numbers, if not more, of CEF which were stained blue in
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FIG. 12. P-Gal staining of chicken embryo fibroblasts to 
determine transfection efficiency. Plasmid CMV-f3-Galactosidase 
was used to cotransfect with the apoA-I promoter-reporter constructs 
into CEF either infected with RCAS vector or RCAS V J-1. After 96 
hours of infection, P-Gal staining experiments were performed on 
RCAS CEF or v-Jun CEF to determine the transient transfection 
efficiency of these cells.
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CEF infected with RCAS VJ-1 compared to control CEF infected with RCAS vector. 
These results suggest that indeed, the decrease of apoA-I promoter activity in response to 
v-Jun overexpression is due to repression of apoA-I transcription by v-Jun. Taken 
together, these results indicate that there might be more than one responsive element 
scattered within nucleotides -311 to +19 o f the apoA-I promoter. Repression o f apoA-I 
transcription by v-Jun may be through interactions among trans-acting nuclear factors 
bound to these different cis-acting elements.
The homologous enhancer does not mediate repression by v-Jun
In the experiments above, we added a homologous enhancer to the apoA-I 
promoter-reporter constructs to increase promoter activity so that we could view 
repression by v-Jun. In order to make sure that this enhancer element was not 
contributing to v-Jun repression, we inserted it downstream in a forward orientation into 
the plasmid pCAT-promoter (Promega) (Fig. 13 and 14). pCAT-promoter constructs 
with or without the homologous enhancer were transiently transfected into CEF either 
infected with RCAS VJ-1 or RCAS vector alone. The CAT activities of the plasmids 
were assayed. For both plasmids, even though the plasmid with the enhancer has higher 
activity than the one without, their respective CAT activities were similar in either 
control CEF or CEF overexpressing v-Jun, suggesting that the activities of neither 
plasmid is affected by v-Jun overexpression. These results indicate that the enhancer 
does not mediate repression and the repression of apoA-I transcription by v-Jun is 
mediated through the apoA-I promoter region.
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FIG. 13. The homologous enhancer does not mediate 
repression by v-Jun. The homologous enhancer was inserted 
downstream in a forward orientation into pCAT-promoter 
(Promega). The plasmids with or without the enhancer were 
transiently transfected into CEF either infected with vector (RCAS) 
or RCAS VJ-1 (v-Jun). The infected cells were harvested 96 hours 
later and CAT activity was assayed. (A), Schematic representation 
of pCAT-promoter without or with the chicken homologous 
enhancer. (B), Autoradiography of CAT assay.
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v-Jun
FIG. 14. The homologous enhancer does not mediate repression by 
v-Jun -  quantitation of CAT assay. 5 pg o f pCAT-promoter plasmids with 
or without enhancer were transiently transfected into CEF either infected with 
RCAS vector (RCAS) or RCAS V-l (v-Jun). The infected cells were 
harvested 96 hours later and CAT activity was assayed. Results are presented 
as percentage of CAT acetylation. The lanes in this figure are the same as 
that in the legend to Figure 13.
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V-JUN REPRESSES APOA-I TRANSCRIPTION THROUGH A MECHANISM 
THAT DOES NOT INVOLVE DIRECT BINDING TO THE APOA-I PROMOTER
The deletion analysis described above suggested that the v-Jun responsive 
elements lie somewhere within the -311 to +19 promoter fragment, possibly within the 
first 60 nucleotides. Because our most dramatic effect was observed with the -311 to 
+19 promoter fragment, we next analyzed the protein-DNA interactions that occur on this 
region in the presence or absence o f v-Jun overexpression. To do this, a series of gel 
mobility shift assays and supershift assays were performed.
No difference in DNA binding between control CEF or CEF overexpressing v-Jun 
when the apoA-I promoter region —311 to 19 was used as probe
The different promoter response to v-Jun overexpression could be due to a 
difference in binding to the apoA-I promoter or to a difference in transcriptional 
activation. To determine if there is any difference in DNA binding between nuclear 
proteins from CEFs either infected with RCAS vector or RCAS VJ-1, gel mobility shift 
assays were performed using the -311 to +19 promoter fragment as labeled probe. The 
nuclear protein binding was analyzed on a 6% acrylamide gel (Fig. 15). A wide complex 
was formed and the binding is specific, as the complex was completely competed by 100- 
fold excess of unlabeled probe but not by 100-fold excess of non-specific 
oligonucleotides. Yet there is no difference in the binding pattern between nuclear 
extract from RCAS CEF and RCAS VJ-1 CEF. These results suggest that there are 
nuclear factors in both RCAS-VJ-I CEF and control RCAS CEF that specifically bind to 
the apoA-I promoter. The 330-bp fragment contains many potential transcription factor 
binding sites, as shown in figure 17. We see a wide smear that indicates binding by a
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the apoA-I prom oter region -311 to +19
RCAS VJ-1
FIG. 15. Gel mobility shift analysis of the apoA-I promoter -  
311 to +19. The apoA-I promoter -311 to +19 fragment was labeled as 
probe. 1 pg of labeled probe was used to incubate with 5 pg of nuclear 
extracts from CEFs either infected with RCAS vector or RCAS VJ-1 
for 15 min on ice. 100-fold excess of unlabeled probe was added as 
specific competitor. 100-fold excess of unlabeled non-specific 
oligonucleotides was added as non-specific competitors (NC). The 
reaction mixtures were analyzed on 6% acrylamide gel. NS oligo: non­
specific similar length oligonucleotides.
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number of different transcription factors. With the probe of this size, we were not able to 
resolve any difference in DNA binding between RCAS VJ-1 CEF and control RCAS 
CEF under our experimental conditions.
V-Jun does not bind to the apoA-I promoter
To determine if v-Jun oncoprotein binds to the apoA-I promoter directly or if v- 
Jun is even present in the protein-DNA complexes formed between nuclear factors and 
the apoA-I promoter, supershift assays with anti-Jun antibody were performed. The 
rabbit polyclonal anti-Jun antibody is raised against c-Jun amino terminal residues 91 to 
105. The -311 to +19 apoA-I promoter fragment was labeled as probe to incubate with 
nuclear extracts from RCAS VJ-1 CEF or control RCAS CEF. The anti-Jun antibody 
was added 15 minutes after the probe was added. The antibody was not able to supershifit 
the specific binding in either RCAS VJ-1 CEF or control RCAS CEF (Fig. 16A). To 
determine the ability o f the anti-Jun antibodies to supershift the specific binding where 
Jun is involved, supershift assays were performed using AP-1 consensus oligonucleotides 
as labeled probe to incubate with nuclear extracts from both RCAS-VJ-1 CEF and control 
RCAS CEF (Fig. 16B). AP-I consensus probe elicited a strong protein-DNA binding. 
The binding is specific, as the binding was completely abolished by 100-fold excess 
unlabeled probe but not by 100-fold excess non-specific oligonucleotides. Addition of 
the specific anti-Jun antibody supershifted the AP-1 specific binding, suggesting that 
under our supershift experimental condition the specific anti-Jun antibody is able to 
supershift the protein-DNA complex when v-Jun is involved. Taken together, these 
results indicate that v-Jun neither binds to the apoA-I promoter directly nor is present in
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FIG. 16. Supershift assays of the apoA-I promoter with anti-Jun 
antibody. The -311 to +19 apoA-I promoter fragments and AP-1 specific 
oligonucleotides were labeled as probes. 1 pg of labeled probes was used to 
incubate with 5 pg (A) or 16 pg (B) of nuclear extracts from CEF either infected 
with RCAS VJ-1 or RCAS vector for 15 min on ice. 2 pi rabbit polyclonal anti- 
Jun antibodies were added. The reaction mixtures were run on 6 % acrylamide 
gel. A, Supershifts of the apoA-I promoter probe with anti-Jun antibody. B, 
Supershifts of AP-1 consensus oligo probe with anti-Jun antibody. Anti-Jun 
antibody: rabbit polyclonal anti-Jun antibody corresponding to Jun protein 
amino terminus (residues 91 to 105). NONE/SC: no antibody, only 100-fold 
excess of non-specific oligonucleotides as non-specific competitor.
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the protein-DNA complexes, and that v-Jun modulates apoA-I gene expression through 
an indirect mechanism.
Putative binding sites for known transcription factors within the apoA-I promoter
region
DNA sequences of the chicken apoA-I promoter nucleotides -311 to +21 
upstream of its transcription start site have been previously reported (118,119).
Computer analysis o f the DNA sequences revealed that there are many putative binding 
sites for known transcription factors located within this promoter region (Fig. 17). Yet, 
surprisingly, no AP-1 consensus site was found in this region. Among these putative 
binding sites, EGR-1, HNF-5, Spl, CTCF, GCF, and AP-2 sites are of particular interest. 
Early growth response factor 1 (EGR-1), which is transiently expressed in various 
pathophysiologic states of the liver, was found to activate the apoA-I expression and 
overcome ARP-1-mediated repression in HepG2 cells (142). It is also involved in the 
induction o f human apoA-I gene expression by the experimental nephritic syndrome in 
transgenic mice (143). HNF-5 is a liver-enriched nuclear factor and its binding sites are 
found to be located close to those of other liver-specific factors (144). Spl is a 
ubiquitous transcription factor frequently associated with promoter activation. AP-2 has 
been shown to be either a transcriptional repressor (145) or an activator (146). Some 
studies have shown that CpG methylation inhibits proenkephalin gene expression by 
blocking AP-2 binding (139). CTCF was first identified as a zinc-finger nuclear factor 
binding to CCCTC-motif within oncogene c-myc promoter (147). Its amino acid 
sequences are highly conserved among species, with chicken and human CTCF sharing 
93% homology (148). It was found to repress transcription o f several genes, including
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
56
-311 GGTACCAACC CGG CG CCCG G  G C T CTGCG C C  A A T CCCCGGG GGCTGCGAGG
Pcf| Rp̂ j P̂-2 | EtCFI gc?1 Rp̂ l gcF]
-261 GGCCCCGGCC GGGCCGGAAT T TG G G TC A C C  CGCAGCGTAA A C A T C T C C T C  
fcCFl pATA-11
-211 GGCCAACGCC GCATCCCCG G  G G AG CTCCTG  TTTG CTG AG G  CTCTG C A A A G  
Rp-lj lTCF-1 | HNF-5| fC F -1 |
-161 CGGCGCTCCT T G G CCG G CTC TCCCG G G G CC G TGCGCACGA T C C T T G A A C T  
(3CFl g C F l MTF-1/MEP-ll
- 1 1 1  CTACGCGCCA C A TCG CCCG C GCCGGGAGTG A T TT C T TG G G  CTGCGGCGCT  
|3CF| £G R -1| g C F ]
-61 G G C TTAT C TC  CTGCGGGAAC T G C C C C T C C T  G CATAAATAG  CGGCGGCGGG  
PATA-1|
-11 GAACCGCGGG CTCACACG G G  ACG AG CAG TG  CG
FIG. 17. DNA sequences of the chicken apoA-I gene 
promoter. Potential binding sites for transcription factors are shown. 
CAAT box and TATA box are underlined. EGR-1: early growth 
response factor 1; GATA-1: erythroid transcription factor. GCF: 
epidermal growth factor negative regulator. MTF-1: metallothionein 
(MT) factor 1; CTCF: CCCTC-binding factor.
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c-myc (148) and lysozyme (149). Recently, studies have shown that CTCF binds to 
chicken beta-globin 42 bp insulator for enhancer blocking activity in human cells and it is 
suggested that directional enhancer blocking by CTCF is a conserved component o f gene 
regulation in vertebrate (150). GC factor (GCF) is reported to be a transcriptional 
regulator that binds to specific GC-rich sequences in the epidermal growth factor (EGF) 
receptor gene promoter and represses its transcription (151,152). Studies also showed 
that GCF represses transcription o f other growth factor/receptor genes (153,154). 
Multiple nuclear factors from CEF bind to the overlapping oligonucleotides from 
the apoA-I promoter but the protein-DNA interactions are not affected by v-Jun 
overexpression
The apoA-I promoter region contains clusters of putative binding sites for many 
transcription factors. We speculated that there are many nuclear proteins from CEF 
nuclear extracts binding to the apoA-I promoter thus masking any difference in DNA 
binding in response to v-Jun overexpression when the long DNA fragment of the 330-bp 
apoA-I promoter was used as a probe. To further investigate DNA binding properties of 
nuclear proteins from RCAS VJ-1 CEF compared to that from control CEF, six 
overlapping oligonucleotides encompassing the 330-bp apoA-I promoter region were 
synthesized and individually used in gel mobility shift analysis. Fig. 18A shows 
schematic representations of these oligonucleotides. This approach was designed to 
examine thoroughly the DNA binding properties of nuclear factors in CEF to the apoA-I 
promoter and unveil differences in DNA binding, if there is any, between CEF infected 
with RCAS-VJ-1 and control CEF infected with vector RCAS.



















FIG. 18. Gel mobility shift analysis o f oligonucleotides -311 
to -244 of the apoA-I promoter. Six oligonucleotides were made to 
encompass the 332-bp long chicken apoA-I gene promoter region 
(positions -311 tO +21). 1ml of each labeled oligo was used as probe 
to incubate with 16 mg of nuclear extracts from CEFs either infected 
with RCAS VJ-l or RCAS vector for 15 min on ice. 100-fold excess 
unlabeled oligonucleotides were added as competitors. A, Schematic 
representation of oligonucleotides encompasses the apoA-I promoter 
region -311 to +21. B, Gel mobility shifts of oligonucleotides -311 to 
-244.
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When oligonucleotides -311 to -244 were used as labeled probes in gel shift assays, an 
intense complex was formed (Fig. 18B). The binding is specific as it was completely 
competed by 100-fold excess unlabeled probe. The -311 to +19 promoter fragment was 
also able to abolish the band completely. AP-1 specific competitor was not able to 
compete for the band, again suggesting that transcription factor complex AP-1 is not 
involved in binding to this fragment. No differences in DNA binding are observed 
between RCAS-VJ-1 CEF and control RCAS CEF.
When oligonucleotides —251 to -192 were labeled and used as probes, one intense 
complex was formed in both RCAS-VJ-1 CEF and control CEF (Fig. 19A). The binding 
is specific as the complex was completely competed by 100-fold excess unlabeled probe. 
AP-1 specific oligonucleotides were not able to compete for the binding in either RCAS 
CEF or VJ-1 CEF. Again, no differences in DNA binding between control CEF and CEF 
overexpressing v-Jun were observed.
When oligonucleotides -211 to -142 and oligonucleotides —41 to +21 were 
labeled as probes, one specific complex was formed in each gel shift assay (Fig. 19B and 
Fig. 19D). AP-1 specific oligonucleotides were not able to compete for the specific 
binding and no differences in DNA binding between RCAS VJ-1 CEF and control RCAS 
CEF were observed. When oligonucleotides -91 to -26 were labeled as probe, no 
distinctive band was formed and no differences in DNA binding between RCAS-VJ-1 
CEF and control RCAS CEF were observed (Fig. 19C). Taken together, these results 
suggest that there are multiple nuclear factors from CEF that bind to the apoA-I 
promoter, but the protein-DNA interactions are not affected by v-Jun overexpression.
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FIG. 19. Gel mobility shift analysis of apoA-I promoter 
oligonucleotides -251 to -192, -211 to -142, -91 to -26, and -41 to 
+21. 1 pi o f labeled oligonucleotides were used as probes to 
incubate with 16 pg o f nuclear extract from CEFs either infected 
with VJ-1 or RCAS vector for 15 min on ice. 100-fold excess of 
unlabeled nucleotides were added as competitors. A, Gel shifts of 
oligonucleotides -251 to -192. B, Gel shifts of oligonucleotides of 
-211 to -142. C, Gel shifts o f oligonucleotides -91 to -26. D, Gel 
shifts of oligonucleotides -41 to +21. NS OLIGO: non-specific 
oligonucleotides.
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AP-1 specific oligonucleotides compete for the nuclear factors that bind to the apoA- 
I oligonucleotides -156 to -85
More gel shift assays were performed with the apoA-I oligonucleotides -156 to -  
85 as labeled probe. This fragment contains putative binding sites for EGF negative 
regulator GCF, early growth response factor 1 (EGR-1), a region that is homologous to 
mammalian apoA-I enhancer element C (site C), and a CAAT box (shown in Fig. 20A).
In the gel shift assay shown in Fig. 20B, a weak complex was formed in both control 
CEF and CEF overexpressing v-Jun. The binding is specific, as the complex was 
completely competed by 100-fold excess unlabeled probe. AP-l specific 
oligonucleotides were able to compete for the specific binding completely in RCAS VJ-l 
CEF, and to a lesser degree, in control RCAS CEF, suggesting that AP-1 specific 
oligonucleotides somehow interfere the protein-DNA interaction between the nuclear 
factor and the apoA-I promoter oligonucleotides -156 to -85  in CEF overexpressing v- 
Jun. HNF-3 specific oligonucleotides, Spl specific oligonucleotides and similar length 
non-specific oligonucleotides were not able to compete for the specific binding. These 
results suggest two possibilities. First, the nuclear factors in VJ-I CEF that bind to the 
apoA-I promoter oligonucleotides also recognizes the AP-1 consensus site, even though 
there is no AP-1 consensus binding site within the apoA-I promoter fragment. Second, v- 
Jun interferes with the binding of the nuclear factor to the apoA-I promoter -156 to -85. 
BOTH DNA BINDING SPECIFICITY AND HETERODIMERIZATION OF V- 
JUN CONTRIBUTE TO ITS REPRESSOR ACTIVITY
To further elucidate the molecular mechanisms by which v-Jun oncoprotein 
represses apoA-I gene transcription, a structure-and-function approach was developed to
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FIG. 20. Gel mobility shift analysis of the apoA-I promoter 
oligonucleotides -156 to -85. 1 mg of labeled oligonucleotides -156 to - 
85 were used as probes to incubate with 16 mg of nuclear extracts from 
RCAS VJ-1 CEF or control CEF for 15 min on ice. 100-fold excess of 
unlabeled oligonucleotides was added as competitors. The reaction 
mixtures were run on 6% acrylamide gel. A, DNA sequences of 
oligonucleotides -156 to -85. Some putative binding sites for known 
transcription factors, CAAT box and TATA box are shown. Site C: a 
homologous region to human apoA-I enhancer element C. B, Gel shifts 
of oligonucleotides -156 to -85. NS oligo: non-specific oligonucleotides. 
HNF-4, AP-1 and Spl oligonucleotides: oligonucleotides contain known 
or consensus binding sites for these transcription factors, respectively.
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investigate systematically the biochemical requirement for repression of apoA-I 
transcription by v-Jun.
The functional and structural domains of v-Jun have been well characterized. The 
structural domains include: (1) A leucine zipper motif located at the carboxyl terminus, 
(2) A basic DNA binding domain immediately adjacent to the leucine zipper domain at 
carboxyl terminus, and (3) A transactivation domain located at the amino-terminus of the 
protein (see Fig. 1 and 2). Three well-defined biochemical functions of Jun are assigned 
to the structural domains: the ability to dimerize to the leucine zipper domain; the ability 
to bind to a specific DNA sequence to the basic DNA binding domain; and the ability to 
activate or repress a responsive gene to the transactivation domain.
Our previous results indicate that v-Jun does not bind to the apoA-I promoter 
directly and that v-Jun is not even present in the protein-DNA complexes formed 
between CEF nuclear factors and the apoA-I promoter. These results suggest that v-Jun 
represses apoA-I transcription through an indirect mechanism. Several possible indirect 
mechanisms include protein-protein interactions, promoter modification, secondary gene 
expression regulation, and reduction of transactivation potential of an activator (Fig. 6).
The protein-protein interaction mechanism involves competition for binding of 
activators or competition with activators for a limiting common coregulator or general 
transcription factors by v-Jun. Methylation of the apoA-I promoter by v-Jun 
overexpression may result from upregulation of methyltransferase, which indicates that 
the DNA binding and transactivation ability of v-Jun would be necessary for repression. 
Similarly, the DNA binding specificity and transactivation activity of v-Jun will be 
absolutely necessary for upregulation of a repressor or downregulation of an activator of
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apoA-I transcription by v-Jun through secondary gene regulation mechanisms. To sort 
out some o f these possibilities, a panel o f v-Jun mutants was selected.
A schematic representation of various v-Jun mutants is shown in Figure 21. The 
transactivation domain o f v-Jun encompasses the major part o f the amino-terminus. To 
determine the role played by the v-Jun transactivation domain in its repressor activity, 
two amino-terminal mutants were selected. Mutant VJ-3 has a portion of its amino- 
terminal transactivation domain (108 amino acids) deleted. This deleted region contains 
acidic region I and II that are important for Jun transactivation activity. Mutant VJ8Nco 
has 128 amino acids of the v-Jun amino terminus deleted. This region contains all three 
independent acidic regions I, II, and III that are important for Jun transactivation.
Dimerization is a prerequisite for Jun to function. Dimerization is mediated 
through a leucine zipper region near the carboxyl terminus. Jun can form dimers with 
Fos, ATF/CREB family members as well as with other members o f the Jun family. 
Previous studies have shown that the Jun homodimer is sufficient to induce cell 
transformation and that heterodimerization with Fos- or Fos-related proteins is not 
necessary (134). To examine the ability o f v-Jun to repress apoA-I transcription in CEF 
without the interaction with other AP-1 family members, mutant VJGLZ was selected.
The leucine zipper dimerization domain of this mutant has been replaced with that of the 
yeast transcription factor GCN4 (134). GCN4 is a bZIP protein that can only 
homodimerize (134). The resulting chimeric protein VJGLZ retains all o f the DNA 
binding and transcriptional activation domains of v-Jun but is incapable o f forming 
heterodimers with other bZIP proteins but itself.
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FIG. 21. Structure-and-function analysis of v-Jun 
functional domain required for its repressor activity-schematic 
representation of v-Jun and various v-Jun mutants.
Retroviruses containing wild-type V-Jun and various v-Jun 
mutants along with control vector RCAS were used to infect CEFs.
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Jun is a nuclear protein with specific DNA binding activity. This DNA binding 
specificity is mediated by the basic domain adjacent to the leucine zipper region in the 
carboxyl-terminus of the protein. To determine how the specific DNA binding ability of 
v-Jun contributes to its repressor activity, an available mutant with altered DNA binding 
specificity was selected. Mutant VJ/C/EBP has its DNA binding specificity altered from 
the Jun DNA binding consensus sequences (TGACTCA) to that of liver-enriched 
transcription factor C/EBP (ATTGCGCAAT) (Bos, et ai., in preparation). The rest o f the 
protein is kept intact and its biological functions as well as its altered DNA binding 
specificity have been tested (Bos, et al., in preparation). Finally, a double mutant, 
VJGLZ/C/EBP, which has both altered DNA binding specificity and limited dimerization 
ability, was also selected (Bos, et al., in preparation).
Retroviruses carrying these mutated v-Jun sequences as well as wild-type VJ-1 
alone with control RCAS vector were used to infect primary CEFs. The infected CEFs 
were harvested 13 days after infection. Total RNA was isolated and northern blot 
analysis was performed to examine the endogenous apoA-I mRNA expression levels 
(Fig. 22). Consistent with our previous results, overexpression of wild-type oncoprotein 
VJ-1 represses apoA-I transcription 5- to 10-fold in CEF as compared to that in control 
CEF (Fig. 22, lane 1 and 2). Overexpression of mutant VJGLZ resulted in 50% reduction 
of apoA-I transcription as compared to control CEF, suggesting that heterodimerization 
of v-Jun with other AP-1 family members contributes to the repression, but is not 
required (Fig. 22, lane 1 and 3). Overexpression of mutant VJ/C/EBP did not have any 
effect on apoA-I gene transcription, suggesting that mutant VJ/C/EBP lost its repressor 
activity and that the DNA binding specificity o f v-Jun is absolutely required for its
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repressor activity (Fig. 22, lane 4). Overexpression o f double mutant VJGLZ/C/EBP did 
not repress apoA-I transcription when compared to that o f the control. Actually, it even 
had a slightly stimulatory effect on apoA-I gene transcription (Fig. 22, lane 5). This 
result suggests that the DNA binding specificity of v-Jun and its heterodimerization 
ability with other AP-1 family members contribute synergistically to repression of apoA-I 
transcription by v-Jun. Overexpression of mutant VJ-3, which has 108 amino acids at the 
amino terminus that contain acidic region I and II deleted, represses apoA-I gene 
transcription to a similar level as wild type VJ-1 does, suggesting that acidic region I and 
II of v-Jun transactivation domain are not required for repressor activity o f v-Jun. 
Overexpression o f mutant VJSNco, which has 128 amino acids at the amino terminus 
domain that contains all three acidic regions deleted, did not have significant effect on 
apoA-I gene transcription, suggesting that independent acidic region III of v-Jun 
transactivation domain located between amino acid residues 105 to 120 is important for 
repression. To confirm that all v-Jun mutants were properly expressed, total cellular 
proteins of infected CEFs were isolated and Western blot analysis probed with various 
anti-Jun antibodies were performed (Fig. 23). Taken together, these results indicate that 
both v-Jun DNA binding specificity and its heterodimerization ability with other AP-1 
family members are required for repression of apoA-I transcription, while DNA binding 
specificity of v-Jun is crucial for the function, heterodimerization plays a minor role. 
Furthermore, the independent acidic region III of v-Jun transactivation domain is 
important for its repressor activity.
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FIG. 22. Structure-and-function analysis of v-Jun 
functional domain required for its repressor activity- 
Northern blot analysis of the endogenous apoA-I mRNA 
levels in response to infection with v-Jun and various v-Jun 
mutants. Retroviruses containing wild-type VJ-1 and various v- 
Jun mutants along with control vector RCAS were used to infect 
CEFs. 13 days after infection, total cellular RNA was isolated 
and Northern blot analysis with the chicken apoA-I gene as 
probe was performed. Lane 1, RCAS vector; lane 2, VJ-1; lane 
3, VJGLZ; lane 4, VJ/C/EBP; lane 5, VJGLZ/C/EBP; lane 6 , VJ- 
3; lane 7, VJSNco.
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FIG. 23. Structure-and-function analysis of v-Jun functional 
domain required for its repressor activity-Western blot analysis of v- 
Jun and various v-Jun mutants protein expression. Retroviruses 
containing wild-type VJ-1 and various v-Jun mutants along with RCAS 
vector were used to infect CEF. 13 days after infection, cell lysates were 
harvested and Western blot analysis were performed to determine the 
expression levels o f v-Jun and v-Jun mutants. The same blot was first 
probed with anti-Jun antibody Ab-1, then reprobed with anti-Jun 
antibody Ab-2. Ab-1 is rabbit polyclonal antibody raised against c-Jun 
DNA binding domain (residues 209 to 225) (Oncogene Science). Ab-2 is 
rabbit polyclonal antibody raised against c-Jun amino terminus (residues 
91 to 105) (Santa Cruz).
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IDENTIFICATION AND CHARACTERIZATION OF AN ENHANCER IN THE 
APOA-I 5’-FLANKING REGION
Presence of Enhancer Sequences in the ApoA-I 5’-FIanking Region
In our previous work, we generated a series o f 5’-deletion mutations of the 
chicken apoA-I gene fused to the chloramphenicol acetyltransferase (CAT) gene and 
transfected these resulting plasmids into primary chicken embryo fibroblasts (CEFs). We 
observed consistently elevated CAT activity in the plasmid containing 6 .8  kb of DNA 
upstream of the chicken apoA-I gene but not in the plasmid containing 6.0 kb of DNA 
upstream of the gene (see Fig. 8 ). We speculated that there is an enhancer located within 
the 800 bp DNA fragment spanning from - 6 .8  kb to -6 .0  kb upstream of the gene. We 
have actually used this region as an enhancer of apoA-I promoter activity in figure 9 and 
figure 10 and found it to function in a distance-independent manner. Because this region 
is so far upstream, it has not been previously characterized.
To further characterize this enhancer sequence in the 5’-flanking region of the 
chicken apoA-I gene, we inserted the 800-bp DNA fragment upstream in both forward 
and reverse orientations into the plasmid containing 330 bp (positions -311 to +19) of the 
chicken apoA-I gene promoter region (Fig. 24). More than 9 to 10-fold increase of the 
chicken apoA-I promoter transcriptional activity was observed when the fragment was 
inserted in the reverse orientation, and nearly a 9-fold increase was observed when the 
fragment was inserted in the forward orientation (Fig. 24A and 24B). These results 
demonstrate that the 800-bp DNA fragment exhibits true enhancer activity as defined by 
distance- and orientation-independent stimulation of promoter activity.




FIG. 24. Enhancer activity in the chicken apoA-I gene. 
Fragment spanning -6.8 kb to -6.0 kb upstream of the transcription 
start site of the apoA-I gene was assayed for enhancer activity. The
fragment was inserted in both orientations upstream into the -311 to +19 
fragment of the apoA-I promoter, which was fused to the CAT gene.
(A), left, schematic representations of the constructs. Right, results of 
transient transfection experiments with CEF. CEFs were transfected 
with equal amounts of the indicated plasmids together with CMV-b- 
galactosidase as a control for transfection efficiency, and CAT activity 
was measured in cell lysates after 48 h. Results are expressed as a -fold 
increase relative to the control promoter p-311/19.CAT and represent the 
mean and S.E. o f at least three independent transfections. (B), 
Autoradiograph o f one of representative CAT assays.
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The enhancer sequence is capable o f stimulating transcriptional activity of 
heterologous promoters
The previous experiments demonstrate that the 800-bp enhancer is capable of 
stimulating transcription from the homologous chicken apoA-I promoter in a distance- 
and orientation-dependent manner in CEF. Next, to determine if  the enhancer is also 
capable of stimulating transcriptional activity o f heterologous promoters, the 800-bp 
fragment was inserted in both orientations downstream of the SV40 early promoter of 
pCAT-promoter plasmid (Promega) and upstream in both orientations o f the human 
apoA-I gene minimal promoter (positions -41 to +234) (Fig. 25). The enhancer activity 
was examined by measuring CAT activities after transiently transfecting the resulting 
plasmids into CEF. The fragment enhanced transcriptional activity of the SV40 early 
promoter modestly but reproducibly by nearly 2 -fold when inserted in the forward 
orientation, but did not have any effect when inserted in the reverse orientation (Fig. 
25A). Interestingly, opposite results were obtained for the human apoA-I minimal 
promoter. The fragment did not have any noticeable effect on transcriptional activity of 
the minimal promoter when inserted in the forward orientation, but enhanced the 
transcription of the human apoA-I minimal promoter nearly 2-fold when inserted in the 
reverse orientation (Fig. 25B). These results show that the enhancer sequence is capable 
of stimulating transcription mediated by both homologous and heterologous promoters. 
The differences in magnitude of stimulation of transcriptional activity by the enhancer 
between the chicken apoA-I promoter and heterologous promoters may be due to the high 
basal activity of SV40 promoter and the human minimal apoA-I promoter. Another
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FIG. 25. Enhancer activity mediated through heterologous 
promoters in CEF. The 800 bp enhancer was inserted in both 
orientations either downstream of the SV40 promoter or upstream of 
the human apoA-I minimal promoter (positions -41 to +234) to 
determine its effect on transcriptional activities of heterologous 
promoters. Transfection experiments were carried out under the same 
conditions as those presented in Fig. 24. (A), the enhancer downstream 
of the SV40 promoter. (B), the enhancer is upstream of the human 
apoA-I minimal promoter.
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possibility is that there may be some specific interactions between the factors bound to 
the enhancer and the factors bound to the chicken promoter.
The enhancer appears to be cell type-specific
To determine if the enhancer element is tissue- or cell-specific, the constructs 
containing either the chicken apoA-I promoter, the human apoA-I minimal promoter, or 
the SV40 promoter, with or without the 800 bp enhancer, were transiently transfected 
into either human hepatic carcinoma HepG2 cells, in which the apoA-I is predominantly 
expressed, or mouse fibroblast NIH 3T3 cells, in which the apoA-I gene is not expressed. 
In neither the HepG2 cells nor the NIH 3T3 cells was the enhancer able to stimulate 
transcription from any o f the promoters tested (Fig. 26). In fact, the enhancer exhibited 
an inhibitory effect on all the promoters in an orientation-independent manner in HepG2 
cells. The inhibitory effect in HepG2 cells was overridden by the strong SV40 enhancer, 
as our data show that the constructs containing both S V40 promoter and S V40 enhancer 
with or without the 800-bp enhancer had similar CAT activities. In NIH 3T3 cells, the 
activities of both the chicken apoA-I promoter and the human apoA-I minimal promoter 
were inhibited by the enhancer in an orientation-independent manner. For the SV40 
promoter, the inhibitory effect o f the enhancer was observed only when the 800 bp 
fragment was inserted in the reverse orientation but not when it was inserted in the 
forward orientation. These results indicate that the activity o f the chicken apoA-I 
enhancer is clearly cell type-specific. The inhibition o f transcriptional activities of the 
chicken apoA-I promoter and the human apoA-I minimal promoter suggests that both cis- 
as well as trans- factors may be involved in the regulation of the enhancer activity.
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FIG. 26. The cell specificity o f the enhancer. The plasmid 
constructs containing the chicken apoA-I promoters (A), the SV40 promoter
(B), the human apoA-I minimal promoter (C), or the SV40 promoter with 
the SV40 enhancer (D), with or without the 800 bp enhancer were 
transiently transfected into either HepG2 cells or mouse fibroblast NIH 3T3 
cells. The transfection experiments were carried out under the same 
conditions described in Fig. 24. Results are represented as percentage 
relative to each individual control plasmid ( those without the enhancer) 
respectively and represent the mean and S.E. o f at least two independent 
transfections. * These experiments were only done once.
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Sequence Information of the Enhancer
To further characterize the enhancer, we cloned the 800bp DNA fragment into the 
pBluescript SK(+) plasmid (Invitrogen) and sequenced it using an automatic sequencer. 
The full-length enhancer is 791 bp long (Fig. 27). Computer analysis o f the full-length 
enhancer revealed that there are many potential binding sites for known nuclear 
transcription factors. Some liver-enriched nuclear factors such as HNF-3, HNF-4,
CAAT/enhancer binding protein (C/EBP) and the ubiquitous Sp-1 transcription factor are 
of particular interest. Liver-enriched nuclear factors HNF-3, HNF-4, and C/EBP have 
been shown to regulate human apolipoprotein gene expression (81,83,88,155). The direct 
protein-protein interaction between self-associated ubiquitous transcription factor Spl 
and the resulting DNA looping mechanism is known to account for many enhancer 
functions (135,136). It was previously observed that the distantly located Sp-1 site 
functions in synergism with the promoter-proximal Sp-1 site to strongly activate 
transcription in vivo. Using conventional and scanning transmission electron microscopy, 
these studies demonstrate that this synergism is likely to be a direct consequence of 
interactions between remote and local Spl, the remote Spl translocated to the promoter 
by a DNA loop. Scanning transmission electron microscopy shows that Spl initially 
forms a tetramer and subsequently assembles multiple tetramers stacked in register at the 
DNA loop juncture (135).
Localization of the Enhancer Activity
To further delineate the activating elements in the full length enhancer of the 
chicken apoA-I gene, a series of deletions of the 791 bp enhancer were made. These are 
shown in Figure 28. One set of deletions extends from the 5’- to the 3’-end of the
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-€800
GGAGGAGTC-C AGA.TTTGCGG GGGCTCAGCA C-GATTTATGC 
MTF-1
GAGCATCTGC CACAGAAGGT AACTGCAGAT CATGAGAGTT 
Myb
GAGCAGCTCA GCTGCAGGCT TGTTCCAACC TGGGGTCGGG 
E2A
CGGG7GCCAG CATCACATGC ACTGACACAA AGGCTGCCTG
GATA-1 TCF-1
AGC-GAAGCAG CCTGCGCTCT GGGCTCCCGC TGCTGGCAAT 
MTF-1
CTC-CGTGGGC C-GCCCTGCAC TGCCAGCACC GCCTTACCTC 
OLIG O III NF-IL6 
TGAGTTTAAC CCCACAGATG TGCAGAAGGA AGGAGGCCGG
T-antigen
CTGCTGGGAA GGATGCTCCA GCAGTGCCGT CTGCATGCTG
CTTCCAAGAG AGTGCATTGA CCCCGCTTTA AAAGCCAGTT 
LFA TCF-1 GATA-1
TCAACCAAAT CTGCTGGTTAG GGTATGACTA AACCGCATTC 
C/EBP
AGCGCTGCCC GTGGGAAACC TTTCCCCAGC TCTGCGGAGC 
AP-2 NF-1L6 SIF
GTCCCTGGCT C-CCGGAGTGG GGCAGGGGCA 
OLIG O IV AP-2 H N F-4 
ACCATTCCCA CAGTTGGAAG GGCCCCGAGG 
















TTGGGTTTTG GTGATGTCAG GGACGAGTCT CTGGAAAGCA CGCATCTTGC CAGCTCCCAG 
HNF-3 GATA-1 H-APF-1 C /E B P OLIGO I GATA-1 AP-2
TGTCTCACTG CTGGCACAAC CAGGGGTTGC TTCCTGCTGA CCATTCCCTG CAAACCTGAT
Ets-1 PEA3 N F-S GATA-1  My b
FIG.27. The nucleotide sequence of the 800 bp enhancer. The 800 bp
enhancer was cloned into plasmid pBluescript SK(+) and was sequenced. The 
full-length enhancer is 791 bp long. Computer analysis revealed that there are 
many potential binding sites for known transcription factors. Underlined are four 
oligonucleotides designed to cover some important potential binding sites and 
were used as probes in the subsequent gel mobility shift assays. Some potential 
sites are shown.
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enhancer (1 to 5). A second set o f deletions extends from the 3’- to the 5’-end of the 
enhancer (6  to 9). Two internal fragments were also made (10 and 11). Each of the 
fragments was inserted in both orientations upstream of the chicken apoA-I promoter 
(positions -311 to +19). The resulting plasmids were transiently transfected into CEFs. 
The results are presented in Figure 28 as CAT activities of these deletion constructs 
relative to that of the plasmid with full-length enhancer, whose activity is set at 100%.
The basal level CAT activity, the transcriptional activity by the promoter in the absence 
of enhancer stimulation, is 10% of the full-length enhancer.
Deletion of the sequences between -6135 to -6010 relative to the apoA-I 
transcription start site (designated 1), which contains a consensus C/EBP site, a AP-2 site, 
two TCF sites, a Est-1 site, a Myb site, and two GATA-1 sites, had reduced the relative 
CAT activity in either orientation more than 50% as compared with the full length 
enhancer. But the deleted fragment alone (designated 9) had barely detectable CAT 
activity in the reverse orientation and had no change in the forward orientation. This 
indicates that transcription factor C/EBP or other transcription factors located in this 
region may play an important role for the enhancer activity, but by itself is not sufficient. 
When the 791-bp fragment was further truncated to position -6250 (designated 2), the 
relative CAT activity was slightly increased in the forward orientation but did not change 
in the reverse orientation. The relative CAT activity of the corresponding 5’-deletion 
containing sequence -6010 to -6250 (designated 8 ) increased 70% when inserted in the 
forward orientation and did not change in the reverse orientation. This indicates that the 
sequence between -6250 to -6135, which contains an HNF-3-like site, a GATA-1 site, 
and an AP-2 site may contribute positively to the enhancer function in an orientation-
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dependent manner. Further truncations to positions -6406 (designated 3), -6557 
(designated 4), and -6629 (designated 5) in the series of 3’-deletions did not have any 
significant effect on relative CAT activity in CEFs compared to the previous deletion, 
regardless of orientation. In contrast, elongation of the corresponding 5’-deletions had a 
significant effect on relative CAT activity. Extending the sequence from -6250 to -6406 
(compare o’-deletions 7 and 8 ) not only fully restored CAT activity when compared to 
the full-length enhancer, but the relative CAT activity of 5 ’-deletion 7 is 70% higher than 
that of the full-length enhancer when inserted in the reverse orientation. The extension 
did not have any effect on CAT activity when inserted in the forward orientation. These 
results suggest that the sequences between -6250 to -6406, which contain a consensus 
Sp 1 site, contain all necessary positive elements for the enhancer function in the reverse 
orientation but not in the forward orientation. Further elongation of the 5’-deletion to 
position -6629 (designated 6 ) resulted in even stronger relative CAT activity when 
inserted in the forward orientation, which is nearly 150% higher than that o f the full- 
length enhancer. When inserted in the reverse orientation, the relative CAT activity of 
deletion 6 is only about 50% of that of the full-length enhancer. These data suggest that 
the sequences between -6629 and -6010 contain all necessary activating elements that 
are crucial for the full-length enhancer activity in the forward orientation but not in the 
reverse orientation. The data also suggest that the sequences between -6629 to -6406, 
which contain putative binding sites for transcription factors HNF-4, NF-IL6 , AP-2, SIF, 
GATA-1, and E2A, may play a crucial role for the enhancer stimulation. To determine 
how this fragment contributes to the enhancer function, a fragment containing only the 
sequence between -6629 and -6406 was made and inserted in either orientation upstream
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of the chicken apoA-I promoter p-311/19.CAT. Surprisingly, the relative CAT activity 
of the resulting construct is below basal level regardless of orientation when it was 
transiently transfected into CEFs. This suggests that the sequences between -6629 and -  
6406 by itself have no stimulatory effect on transcriptional activity of the chicken apoA-I 
promoter. Further truncation of the 5’-end to position -6557 restored 100% of full-length 
enhancer activity when inserted in the reverse orientation and about 80% o f the full- 
length enhancer activity when inserted in the forward orientation. This result clearly 
suggests that there are strong negative regulatory sequences located within the sequences 
between -6629 to -6406 and that regulation o f the enhancer function is complex, 
involving many positive as well as negative modules of the cis-acting elements, and 
many trans-acting transcription factors bound to these cis-acting elements.
Analysis of protein-DNA interaction: possible involvement of the liver-enriched 
Transcription factor C/EBP
To determine which nuclear transcription factors may be involved in regulation of 
the enhancer function, a series of gel mobility gel shift assays were performed. Four 
oligonucleotides (designated I to IV) (Fig. 27) were designed as probes based on deletion 
analysis of the enhancer experiments. These oligonucleotide probes contain putative 
binding sites for some liver-enriched nuclear factors and some ubiquitous transcription 
factors that are known to be involved either in mammalian apoA-I gene regulation or are 
important for enhancer function. Table I summarizes the oligonucleotide sequences and 
similarities of these sequences to the consensus recognition sequence for various 
transcription factors. To identify and confirm the transcription factors that bind to the 
oligonucleotide probes, double-stranded oligonucleotides that represent known strong
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Potential Binding Sites 
NF-IL6  MEP-1
l"1^V — ' g S . p , . ,  GATA^h^ P F - i Relative CAT Activity
C /E B P H N F-4 S p ;  I—=3 H N F-3 C /E B P  p  R
I r ' " i T  I 100% 100%
* CiS|T J  37 £ 6 . 4  32 £  9 2
 — I L A I ~ |  S3 £  0 8  35 £  0  9
I TTiT I 52 £  2 .0  4 9  £  1.3
4 ^  CAT 1 55 £  0 .9  36 ±  3 .5
5 I ' T l  I 41 £ 3 . 6  45 £ 3 . 3
— I i 244 £  1.3 51 £  2 .4
■ ■ ■ ■ ^ ^ 2 5 n U  62 £  9 .0  172 £  3 .2
8  ............... ..............................  ..............................BBBBBBB—4 Z S 2 1 Z 3  62 £  4 9 7 £  13.1
9  ........................................ ...............  .................................................................... ^ C E 5 3 Z H  35 £  0 .8  7 £  0  4
10...................................................................................................... .................................. ............................................... r ^ r  1  5 ± 0 .2  a £  0 .4
11 ................................................................................................................................................  I m  I 77 £  0 .6  108 £  0 .2
12 | " i’ iT I 10 £ 3 . 4  10 £  7 .6
FIG. 28. Deletion analysis of the enhancer activity. Relative CAT 
activity represents CAT gene expression for at least three independent 
transfection experiments. The transfection experiments were carried out 
under the same conditions as described in Fig. 24. AH activities are reported 
relative to the activity o f the full 791-bp enhancer (100%) and S.E. At the 
top are shown potential binding sites for known transcription factors, based 
on computer analysis. These sites all represent similarities to known binding 
sites, though some deviate from consensus sequences. The sites provide a 
basis for selecting deletions and designing further experiments, but do not 
represent identification o f actual sites. F=Forward orientation. R=Reverse 
orientation.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
82
TABLE I
Similarities o f  the sequences o ffour oligonucleotides in the enhancer o f  the chicken 
apoA-f gene to the consensus binding sites fo r various known transcription factors.
Consensus sequences for vertebrate-encoded transcription factors [ 174] were used 
to create a database. The full-length enhancer 791-bp was computer-analyzed. Among
more than 50 sites identified, only most significant sequence similarities are shown.
Source o f  
sequence (Ref)









G T G G A A A G
G T G G T /A T /A T /A G




C T G G A A A
C TG G R A A




TG A T G T
T /A G A T A R




T T T G G G T T T T G
T A T T G A C /T T T A /T G











C /G C G C/G C/G C/G C




G G C A A G G G A A G C
G /T G C A /T A A /G G T /G C /
T C A C /T






C C C A /C N G /C G /C G /C




TG C G C TC
TG C R CN C
IV -6468 to -6462 M E P -1 /M T F -I 7/7
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
83
TABLE II
Specific oligonucleotide competitors [173]
Double-stranded oligonucleotides were constructed to represent known strong 
binding sties for specific individual transcription factors (upper case) with an additional
4-base sticky end (lower case).




AAGGTAGAATGAGTTGTAGGAGGt g e t
Murine 
transthyretin 
enhancer -  
1890 to -  
1866
[167, 168]




promoter -  









promoter -  
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binding sites for individual transcription factors Spl, HNF-3, HNF-4, and C/EBP were 
also synthesized as specific competitors. Table II summarizes the sequences and 
references for these specific competitors.
Radiolabeled double-stranded nucleotides, Oligo I, containing a putative binding 
site for liver-enriched transcription factor C/EBP (Fig. 29A and Table I) were incubated 
with the nuclear extracts from CEFs, and nuclear protein binding was analyzed by gel 
shift assays (Fig. 29B). Two distinct DNA-protein complexes were formed. The binding 
is specific, as the two bands were competed by 100-fold excess o f unlabeled nucleotides, 
but not by unrelated nucleotides that are about the same length (Fig. 29, lane 1,2 and 3). 
The binding was completely abolished by specific competition from unlabeled C/EBP 
specific oligonucleotides (Fig. 29B, lane 4 and Table II), suggesting that Oligo I and 
specific C/EBP oligonucleotides compete for the same nuclear factor binding. A 
reciprocal gel shift assay was performed using the specific C/EBP competitors as 
radiolabeled probes. A single, distinct complex was formed (Fig. 29C). The binding is 
specific as the band was completely competed by unlabeled C/EBP nucleotides.
However, the band was not competed by Oligo I (Fig. 29C, lane 4), suggesting that the 
specific C/EBP Oligonucleotide has higher affinity for C/EBP than Oligo I.
Binding of Liver-enriched Transcription Factor HNF-3 to the Enhancer Element 
Gel shift assays were also performed with Oligo II, which contains an HNF-3 
consensus site and a GATA-1 site (Fig. 30A and Table I). Incubation of radiolabeled 
Oligo II with the nuclear extracts from CEF resulted in two protein-DNA complexes. All 
the complexes are specific as they were completely competed by 100-fold excess 
unlabeled probes. Complex 1 is completely competed by unlabeled HNF-3 specific
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A  Oligo I
-6150 -6103
GTGATGTCAGGGACGAGTCTC.TGGAAAGCACGCATCTTGCCAGCTCCC
| GATA-1 I I I c/EBP l | GATA-1 ]
I H-APR-1 1--------------
OLIGO I
FIG. 29. Gel mobility shift analysis of the enhancer 
fragment oligo I. The labeled double-stranded oligonucleotides 
used for nuclear factor binding as well as competitors are described 
under “Materials and Methods”. All competition experiments were 
performed by adding 100-fold excess of unlabeled double-stranded 
competitors. A, oligo I probe of the enhancer. The sequences and 
putative binding sites for transcription factors are illustrated. B, Gel 
shifts o f Oligo I. C, Reciprocal gel shifts o f specific oligo C/EBP.
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n  Oligo II
-6179 -6136
GGTATGACCAGGACACGTTTGGGTTTTGGTGATGTCAGGGACGAG




“ t*. *? 2 °-COMPET1TORS: u. 2  ffiO in z  -i Uf
Z  «/> X o  o
III o  O  n .
Z  ■*! O o  ®
O  ill 3  J  H!
Z  <A O o  o
I
2 3
FIG. 30. Gel mobility shift analysis of the enhancer 
fragment oligo II. The labeled double-stranded oligonucleotides 
used for nuclear factor binding as well as the competitors are 
described under “Materials and Methods”. All competition 
experiments were performed by adding 100-fold excess of unlabeled 
double-stranded oligonucleotides. A, Oligo II probe o f the enhancer. 
The sequences and putative transcription factor binding sites are 
illustrated. B, Gel shifts of Oligo II probe. C. Reciprocal gel shifts 
of specific HNF-3 oligo.
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competitor, suggesting that Oligo II and HNF-3 specific oligonucleotides compete for the 
binding of the same nuclear factor. The lower band, complex 2, was completely 
competed by Oligo I as well as C/EBP specific competitor (Fig. 30B, lane 4 and 5), 
suggesting that C/EBP family proteins may be involved in the complex. Interestingly, 
when Oligo I was used as a competitor, complex 1 was intensified while complex 2 was 
competed, suggesting that possibly some protein-protein interactions were interrupted 
and a certain balance was shifted. C/EBP specific competitors were able to compete for 
both complex 1 and complex 2 , suggesting that there are some interactions between 
C/EBP family proteins and HNF-3 family proteins.
Reciprocally, when the HNF-3 specific competitor was used as radiolabeled 
probe, two specific protein-DNA complexes were formed (Fig. 30C, lane 1 and 2). 
Although both complexes were competed by Oligo II, competition was greater for the 
upper complex (Fig. 30C, lane 3). C/EBP specific competitors were able to compete for 
the two complexes to a similar degree as Oligo II, further confirming the interactions 
between C/EBP family proteins and HNF-3 family proteins (Fig. 30C, lane 5). Again, it 
is not surprising that as a weaker binding site for C/EBP, Oligo I did not compete with 
the strong HNF-3 specific binding oligonucleotides (Fig. 30C, lane 4). Together, these 
results suggest that HNF-3 family proteins may bind to the enhancer and interact with the 
C/EBP family proteins.
Binding of the Transcription Factor Spl to the Enhancer Element
The results from the deletion analysis experiments show that the sequences 
between -6406 to -6250 are crucial for the full-length enhancer activity. Within this 
DNA fragment, there are a Spl binding site, a GCF site and a NF-IL6  site. Oligo III was
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designed to cover the Spl and GCF sites (Fig. 31 A). Gel shift assays were performed 
using Oligo III as labeled probes. Three protein-DNA complexes were formed (Fig.
31B). The binding is specific as all the complexes were competed by 100-fold excess 
unlabeled probe (Fig. 3 IB, lane 2). Complex 2 was completely competed by 18-bp long 
Spl specific competitors, suggesting that Oligo III and Spl specific oligonucleotides 
compete for the same nuclear factor binding (Fig.3 IB, lane 3). Transcription factor AP-l 
specific competitor was able to partially compete for the lower band, complex 3 (Fig.
31B, lane 4). Interestingly, the DNA fragment o f chicken apoA-I gene 330-bp promoter 
region (positions -311 to +19) was able to completely abolish formation of complex 1 
and complex 2 (Fig. 31B, lane 5), suggesting that the chicken apoA-I promoter region 
contains sequences recognized by the same nuclear factors, possibly Spl.
To further confirm the binding of transcription factor Spl to the enhancer, 
reciprocal gel shift assays were performed using labeled Spl specific competitors as 
probes (Fig. 31C). One major complex and two minor ones were formed. All complexes 
are specific as they were all competed by 100-fold excess unlabeled probes (Fig. 31C, 
lane 1 and 2). Oligo III completely abolished the formation o f all the complexes; 
strongly suggesting that Sp-1 does bind to Oligo III (Fig. 31C, lane 3). The DNA 
fragment from the chicken apoA-I promoter region was able to compete partially for all 
the specific protein-DNA complexes whereas AP-l specific competitors did not have any 
effect (Fig. 31C, lane 4 and 5). Overall, these results suggest that ubiquitous transcription 
factor Sp 1 binds to both the enhancer and the promoter o f chicken apoA-I gene, and that 
Spl-Spl interaction may play a role in transcriptional stimulation of the chicken proximal 
promoter by the distal enhancer.
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„ „ Oligo III-6416 a  -6367
TGGAAGGGCCCCGAGGCTGCGTGGGCGGCCCTGCACTGCCAGCACCGCCT
| _ l S £ l _ GCF
B
PROBE: OLIGO III SP-1
10 u. <t
COMPETITORS: o  Oj Z  Z  £





3 4 3 4 5
FIG. 31. Gel mobility shift analysis of the enhancer 
fragment oligo III. The labeled double-stranded oligonucleotide used 
for nuclear factor binding as well as competitors are described under “ 
Materials and Methods”. All competition experiments were performed 
by adding 100-fold excess of unlabeled double-stranded 
oligonucleotides. A, Oligo III probe of the enhancer. The sequences 
and putative transcription factor binding sites are illustrated. B, Gel 
shifts of Oligo III. C, Reciprocal gel shifts of specific Sp-1 oligo.
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Binding of an unknown nuclear factor to Oligo IV
More gel shift assays were performed with Oligo IV as labeled probes. Oligo IV 
contains a liver-enriched nuclear factor HNF-4-like site, an AP-2 site and a 
Metallothionein (MT) Factor 1 (MTF-1) site (Fig. 32A). One protein-DNA complex was 
formed (Fig. 32B, lane 1). The binding is specific as the complex was completely 
competed for by unlabeled probes (Fig. 32B, lane 2). HNF-4 and AP-l specific 
competitors were not able to compete for the specific binding (Fig. 32, lane 3 and 4), 
suggesting that neither is involved in the protein-DNA complex. This result was further 
confirmed by reciprocal gel shift assays. No binding was observed when the HNF-4 
specific oligonucleotides were used as labeled probes (Fig. 32C). Together, these results 
suggest that an unknown nuclear factor, possibly AP-2 or MTF-1, binds to Oligo IV.






1 I HNF-4__________f I MTF-1 [
AP-2
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FIG. 32. Gel mobility shift analysis of the enhancer 
fragment oligo IV. The labeled double-stranded oligonucleotides 
used for nuclear factor binding as well as competitors are described 
under “ Materials and Methods”. All competition experiments were 
performed by adding 100-fold excess o f unlabeled double-stranded 
oligonucleotides. A, Oligo IV probe o f the enhancer. The sequences 
and putative transcription factor binding sites are illustrated. B, Gel 
shifts of Oligo IV. C, Reciprocal gel shifts of specific HNF-4 oligo.




We have previously reported the identification of the chicken apoA-I gene as a 
negative target of v-Jun overexpression. In this study, we further investigated the 
possible underlying mechanisms by which v-Jun represses apoA-I gene expression. Our 
data presented here demonstrate that v-Jun does not bind to the apoA-I promoter directly 
and suggests that v-Jun regulates apoA-I gene expression through an indirect mechanism. 
In addition, we reported the identification of an enhancer located between -6.8 kb to -6.0 
kb upstream of the transcription start site of the chicken apoA-I gene that stimulates 
transcription from the apoA-I promoter in a distance- and orientation-independent 
manner and thus exhibits enhancer characteristics. We described the characterization of 
nuclear transcription factors Spl, C/EBP, HNF-3, and an unknown factor that interact 
with the cis-acting elements o f the enhancer. We also investigated the functional 
properties and species specificity of the enhancer.
TRANSCRIPITIONAL REGULATION BY V-JUN
The role of v-Jun in transcriptional regulation has been extensively examined in 
recent years. As a major component o f the transcription factor complex AP-l, the Jun 
protein can recognize and bind to specific DNA sequences and regulate target gene 
expression from nearby promoters in the form of a complex with its many dimerization 
partners. In addition, the Jun proteins can also regulate many target genes that do not 
contain AP-l - or CRE-like sites in their promoter region through protein-protein 
interaction with non-leucine zipper transcription factors.
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Our data presented in this study show that v-Jun does not bind to the apoA-I 
promoter directly. Therefore the first repression model (see Fig. 6) involving direct DNA 
binding to the apoA-I promoter is unlikely. Our data favor the indirect models. 
PROTEIN-PROTEIN INTERACTIONS
Protein-protein interaction is a common indirect mechanism found in the 
regulation of many genes. Studies have shown that Jun represses glucocorticoid- 
responsive genes and myogenesis through direct physical protein-protein interactions 
with glucocorticoid receptor and Myo D (37,40). V-Jun may repress either basal or 
activated transcription by competing for binding of activators or competing with an 
activator for a limiting common coregulator or general transcription factors and deplete 
these factors. Our deletion analysis mapped the multiple v-Jun responsive elements to 
the apoA-I promoter -311 to +19 upstream of the gene transcription start site, indicating 
that there may be multiple trans-acting factors that may interact with v-Jun. The apoA-I 
promoter region mediates binding o f many transcription factors including HNF-4, HNF- 
3p, ARP-1, EGR-1, and C/EBP as well as the actions o f many hormones and other 
factors.
The orphan nuclear receptor hepatocyte nuclear factor 4 (HNF-4) is required for 
development and maintenance o f the liver phenotype. HNF-4 activates several 
hepatocyte-specific genes, including the gene encoding apolipoprotein AI (apoA-I). The 
apoAI gene is activated by HNF-4 through a nuclear receptor binding element (site A) 
located in its liver-specific enhancer. Studies have shown that HNF-4 activates apoA-I 
transcription by facilitating assembly of a preinitiation complex intermediate consisting 
of TBP, the TATA box-binding protein component of TFIID and TFIID, via direct
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physical interactions with TFIIB (110). Members of the Jun family of transcriptional 
activators were also reported to interact with both TBP and TFIIB in vitro. TBP binds to 
both the N-terminal activation domain and C-terminal bZIP regions of c-Jun, whereas 
TFIIB binds to only the c-Jun bZIP domain. This interaction requires the dimerization of 
the Jun protein. The ability of the N- terminal activation domains o f c-Jun, JunB, JunD 
and v-Jun to interact with TBP in vitro correlates with their transcriptional activity in 
vivo. It is suggested that the Jun family of activator proteins may activate transcription 
by interacting with the general transcription factors TBP and TFIIB (31). Out results in 
this study did show that the ability of v-Jun to form heterodimers and the acidic region III 
of v-Jun transactivation domain are required for repression of apoA-I transcription. It is 
possible then that v-Jun competes for general transcriptional factors with activators of 
apoA-I transcription such as HNF-4 and depletes these factors thus resulting in reduced 
transcription of the apoA-I gene.
METHYLATION OF THE APOA-I PROMOTER
Methylation is an epigenetic mechanism for modulation of gene expression in 
vertebrates. The process is mediated by an enzymatic methyl transfer reaction at cytosine 
located 5’ to guanine (CpG dinucleotides) residues in the unmethylated nascent DNA 
strand across from methylated CpG dinucleotides. Acquisition of DNA methylation at a 
previously unmethylated site can not be accomplished by maintenance methylation and 
requires de novo methylation (137,156). DNA cytosine-5 methyltransferase is the only 
methyltransferase (Mtase) that has been identified to date in mammalian as well as in 
avian cells (157). Abnormal patterns of DNA methylation are a consistent molecular 
feature of immortalized and neoplastic cells (137). It has been demonstrated that
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overexpression o f murine DNA MTase is transforming for NIH 3T3 cells (158) and that 
cellular levels of DNA MTase increases 20-fold in SV40-transformed human fibroblasts 
and the DNA methylation accounts for the inhibition of collagen VI expression (141).
CpG methylation has long been associated with repressed gene transcription (137- 
141). Recent studies showed that the tissue inhibitor of metalloproteinases-3 (TIMP-3) 
gene is specifically downregulated in neoplastic cells of the mouse JB6 progression 
model. On the basis of 5-azacytidine reversal, the mechanism for this down-regulation 
appears to involve changes in the methylation state of the TIMP-3 promoter. Expression 
of antisense methyltransferase resulted in reactivation of the endogenous TIMP-3 gene 
(159).
Overexpression of v-Jun may upregulate methyltransferase resulting in 
methylation of the apoA-I promoter, which is extremely GC rich. Although we have not 
specifically examined the methylation status o f the apoA-I promoter in v-Jun transformed 
cells, the upregulation of the DNA MTase remains a possibility. Several mechanisms 
have been proposed to explain how CpG methylation affects gene expression. One is that 
methylation at a specific site repels the transcription factors that would normally bind 
there. Repression of proenkephalin gene expression by methylation through repelling the 
binding of the transcription factor AP-2 (139) is one example. Another mechanism is 
that methylation attracts proteins that themselves mediate repression (160-162).
However, in either case, the final effect has to be achieved through changes in DNA 
binding by different transcription factors. Our results show that there is no difference in 
DNA binding of the apoA-I promoter between nuclear proteins from CEF infected with 
RCAS VJ-1 and control CEF infected with vector RCAS alone. If  v-Jun represses apoA-
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I transcription through methylation of the apoA-I promoter, the mechanism will be quite 
different.
SECONDARY GENE EXPRESSION REGULATION
Jun is a ubiquitous transcription factor and regulates expression of many genes. 
The observation that the DNA binding specificity of v-Jun and the acidic region III of its 
transactivation are absolutely required clearly favor the secondary gene regulation 
mechanism. A simple secondary gene regulation event is to upregulate a repressor or 
downregulate an activator o f apoA-I gene transcription. Recent studies showed that 
G 1OBP, a serum-inducible factor, represses transcription of the fibronectin gene through 
binding to the G-rich sequences in the promoter excluding Spl from binding to these 
sequences (163). Further studies revealed that the G10BP-1 gene is a target o f Myc and 
Jun/Fos and that these factors repress fibronectin gene expression through induction of 
G10BP-1 during G 1-to-S phase progression (163,164).
The observation that v-Jun can simultaneously activate and repress different genes 
in CEF illustrates the role o f promoter-specific factors in regulating the activities of v-Jun 
(72,75). The apoA-I promoter region mediates the binding of many transcription factors 
and the actions of many hormones (see Fig. 5 and Fig. 17). Studies have shown that 
EGR-1 activates the apoA-I gene promoter and overcomes orphan nuclear receptor ARP- 
1-mediated repression of the promoter in hepatoblastoma HepG2 cells (142). EGR-1 was 
also involved in the full induction o f human apoA-I gene expression by the experimental 
nephrotic syndrome in transgenic mice (143). EGR-1 is an immediately-early gene 
whose expression is found, in many cases, to be regulated similar to that o f c-Jun. 
Overexpression of v-Jun is known to repress c-Jun expression (165). Other candidate
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
97
genes that may be regulated by v-Jun are GC factor (GCF), CTCF, and AP-2. GCF was 
first identified as a transcription factor that binds to the GC rich promoter region of EGF 
receptor and represses its transcription (151). Later studies have shown that GCF 
represses the transcription of several other growth factor/receptor genes, including 
insulin-like growth factor receptor (153,154). CTCF was first identified as a zinc-finger 
nuclear factor binding to a CCCTC-motif within oncogene the c-myc promoter (147). Its 
amino acid sequences are highly conserved among species, with chicken and human 
CTCF sharing 93% homology (148). It was found to repress transcription of several 
genes, including c-myc (148) and lysozyme (149). Recently, studies have shown that 
CTCF binds to the chicken beta-globin 42 bp insulator for enhancer blocking activity in 
human cells and it is suggested that directional enhancer blocking by CTCF is a 
conserved component of gene regulation in vertebrates (150). AP-2 has been reported as 
both an activator and repressor of transcription (145,146). More recently, studies 
reported that expression of the apoA-I gene declines with age both in humans and in rats. 
The age-dependent changes of DNA binding activity to two proximal sites, B and C of 
the apoA-I promoter, are responsible for the decline in apoA-I expression. Decreased site 
B binding activity correlated with lower mRNA levels encoding the activator, HNF-3p. 
The age-dependent change in the pattern of binding to site C was due to a switch from the 
activator, HNF-4, to the repressor, ARP-1 (104). It is reasonable to speculate that 
overexpression of v-Jun interferes with the cellular balance of apoA-I regulators which 
may affect apoA-I transcription without a pronounced change in DNA binding activity. 
Treatment with the protein synthesis inhibitor cycloheximide may be needed to determine 
whether a labile protein is necessary for repression by v-Jun.
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REDUCTION IN TRANSCRIPTION POTENTIAL BY V-JUN
In this study, even though extensive efforts were made to unveil differences in 
DNA binding o f the apoA-I promoter between nuclear extracts from CEF infected with 
RCAS-VJ-l or control CEF, we did not detect any difference in DNA binding under our 
experimental conditions. Though many nuclear factors from CEF bind to the apoA-I 
promoter specifically, supershift assays demonstrated that v-Jun is not even present in the 
protein-DNA complexes. Yet, the DNA binding specificity o f v-Jun, its ability to 
heterodimerize, and the acidic region III of its transactivation domain are required for 
repression of apoA-I transcription by v-Jun. Taken together, these results prompts us to 
speculate that v-Jun may repress apoA-I transcription by reducing the transactivation 
potential o f an activator.
Studies have shown that c-Jun inhibits insulin gene transcription in pancreatic 
beta cells by reducing the transactivation potential o f the E2A proteins present in the ICE 
activator complex (42). The pancreatic beta-cell-type-specific transcription of the insulin 
gene is principally controlled by trans-acting factors which influence insulin control 
element (ICE)-mediated expression. The ICE activator is composed, in part, o f the basic 
helix-loop-helix proteins E l2, E47, and E2-5 encoded by the E2A gene. It was found 
that ICE activation in beta cells was repressed in vivo by c-Jun. C-Jun was shown to 
specifically repress the transactivation potential of the E2A proteins. Repression of E2A 
was mediated by the basic leucine zipper domain of c-Jun, which is also the essential 
domain of this protein necessary for controlling ICE activator-stimulated expression in 
vivo. It is possible that v-Jun affects the transactivation potential o f an activator without 
affecting its DNA binding ability.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
These mechanisms described above are not exclusive. V-Jun may employ more 
than one mechanism to repress target gene transcription.
In summary, in this study, the v-Jun responsive elements were mapped within 
nucleotides -311 to +19 upstream of the apoA-I transcription start site. Within this 
fragment, there are multiple elements which may mediate the repressor activity of v-Jun. 
Gel mobility shift assays and supershift assays demonstrated that v-Jun does not bind to 
the apoA-I promoter directly. Biochemical analysis of functional domains of v-Jun 
indicates that DNA binding specificity of v-Jun is absolutely required for repression of 
the apoA-I transcription, and that its ability to heterodimerize with diverse partners also 
plays a role. In addition, the sequences between amino acid residues 108 to 128 in the 
amino terminus o f v-Jun proteins that contain the acidic region III o f its transactivation 
domain are important for its repressor activity. Taken together, these results clearly 
suggest the mechanism by which v-Jun represses apoA-I transcription does not involve 
direct DNA binding of v-Jun to the apoA-I promoter but occurs by an indirect 
mechanism.
THE ENHANCER CONSISTS OF MANY MODULES, BOTH POSITIVE AND 
NEGATIVE
Transcription of the chicken apoA-I gene is readily detectable in chicken embryo 
fibroblasts, yet the apoA-I basal promoter is extremely weak when tested in transient 
transfection assays. Optimal transcription o f the chicken apoA-I gene, like that of many 
genes, might depend on the presence of one or more enhancer regions which stimulate 
transcription from the proximal promoter in a distance- and orientation-independent 
manner. In this study we reported the identification of an enhancer located between -6.8
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kb to -6.0 kb upstream o f the transcription start site of the chicken apoA-I gene that 
stimulates transcription from the apoA-I promoter in a distance- and orientation- 
independent manner and thus exhibits enhancer characteristics. The characterization of 
nuclear transcription factors Spl, C/EBP, HNF-3, and an unknown factor that interacts 
with the cis-acting elements of the enhancer, the functional enhancer properties, and its 
species specificity were also investigated.
The 800 bp full-length enhancer was first identified by transient transfection 
assays using a series of deletion mutations o f the chicken apoA-I gene 5’-flanking region 
(75). Insertion of this fragment upstream in both orientations o f the chicken apoA-I 
promoter (positions -311 to +19) resulted in 9- to 12-fold increases in transcriptional 
activity. The complexity o f the enhancer regulation was suggested by deletion analysis 
of the enhancer.
While the 791-bp full-length enhancer is orientation-independent, two deletion 
fragments, deletion 6 and deletion 7, were not (see Fig. 28), both exhibiting higher than 
full-length enhancer activity in one orientation, but not the other. Deletion 11, a 152-bp 
internal fragment spanning -6557 to -6406, could confer 100% of the full-length 
enhancer activity in the reverse orientation and 80% of the full-length enhancer activity 
in the forward orientation. A 73-bp long 5’-extension from -6557 to -6629 completely 
abolished the enhancer activity in both orientations. Meanwhile, 3’-deletions from -6135 
to -6010 (126-bp) reduced the enhancer activity to 30% of the full-length enhancer, but 
by itself, it only showed 35% enhancing activity in the forward orientation and basal 
level in the reverse orientation. Taken together, these results suggest that the enhancer is 
composed of many domains, both positive and negative. Interactions among nuclear
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
101
factors bound to different enhancer modules contribute to the complexity of the enhancer 
regulation.
CELL TYPE SPECIFICITY OF THE ENHANCER
The enhancer is strictly cell type-specific. It modestly stimulates transcriptional 
activity mediated by heterologous SV40 promoter and the human apoA-I minimal 
promoter in CEFs. But when human hepatoma HepG2 cells or mouse fibroblasts 
NIH3T3 were transfected with plasmids containing either the homologous chicken apoA- 
I promoter or heterologous promoters, the enhancer exhibits a pronounced inhibitory 
effect. The SV40 enhancer is able to override the inhibition in both HepG2 and NIH3T3 
cells when inserted in the same plasmid construct as the chicken apoA-I enhancer. In 
human breast carcinoma MCF7 cells, the enhancer has no effect on all the promoters 
tested (data not shown). Two interesting questions arise. What cis-acting and trans­
acting factors contribute to the expression of the apoA-I gene in CEF? What differences 
of trans-acting factors exist between CEFs and HepG2 or NIH3T3 cells to make the 
enhancer stimulatory in one cell type and inhibitory in others? The control of 
differentiated gene expression lies mainly at the level o f transcriptional initiation. The 
mammalian apoA-I gene has a powerful liver-specific enhancer located within -220 to -  
110 nucleotides upstream of the transcription start site. Our study here shows that 
chicken apoA-I gene has a strong cell-specific enhancer located within -6800 to -6000 
nucleotides upstream o f the transcription start site. Cell-specific DNA elements 
apparently mediate their effects on transcription through interaction with trans-acting 
nuclear factors. It has long been demonstrated that liver-specific (or liver-enriched) 
transcription factors exist and participate in the activation of more than one gene in liver
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(166-168). One scheme of explanation for differential regulation o f the chicken apoA-I 
gene expression is that the gene has multiple activating sites that are simultaneously 
required for activity, and that some of the liver-enriched factors are active in CEF but are 
not in mammalian cell types. Results from our study certainly support this possibility.
We showed that there are liver-enriched nuclear factors such as C/EBP and HNF-3 in 
CEF nuclear extracts, and that the chicken apoA-I enhancer contains binding sites for 
these factors. One obvious difference between CEF and HepG2 cells is that CEFs do not 
contain the liver-enriched nuclear transcription factor FTNF-4. It is possible that HNF-4 is 
responsible for the inhibitory effect exhibited by the enhancer in HepG2 cells. However, 
this does not explain the inhibition by the enhancer in NIH3T3 cells that do not have high 
level of endogenous FTNF-4 (106,169).
The cell type specificity as well as the function o f the enhancer is mediated 
through interactions between its cis-acting elements and nuclear transcription factors. 
Computer analysis o f the full-length enhancer revealed that there are many putative 
binding sites for transcription factors. Based on the computer analysis, we designed four 
oligonucleotides as probes in gel mobility shift assays. These four probes contain 
binding sites for ubiquitous transcription factor Spl and liver-enriched transcription 
factors C/EBP, HNF-3 and HNF-4, respectively. Gel shift results from our study 
suggests that Spl, C/EBP, HNF-3, and an unknown factor from CEF nuclear extracts all 
bind to the enhancer, while HNF-4 is not likely to be present at high levels in CEF. 
TRANS-ACTING NUCLEAR FACTORS
Ubiquitous transcription factor Spi is a constitutive activator o f housekeeping 
genes and acts by binding to GC boxes in their proximal promoter regions. It has also
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been found to play an important role in the activity o f several enhancers, including the 
apoE upstream regulatory element (170), the immunoglobulin-K-3 enhancer (171), the 
apo(a)-plasminogen intergenic region enhancer (172), and a-fetoprotein enhancer (173). 
Spl-Spl binding between proximal promoter and distal enhancer is a known mechanism 
for long distance promoter stimulation (135,136). In these studies, binding of human 
transcription factor Spl to 10-base-pair G+C-rich elements ("GC boxes") located at -100 
and +1700 relative to the RNA start site was examined to investigate the physical basis of 
long-range enhancer effects between distal and proximal elements in an eukaryotic 
promoter. It was previously observed that the distantly located Sp-1 site functions in 
synergism with the promoter-proximal Sp-1 site to strongly activate transcription in vivo. 
Conventional and scanning transmission electron microscopy demonstrate that this 
synergism is likely to be a direct consequence of interactions between remote and local 
Spl, the remote Spl translocated to the promoter by a DNA loop. Scanning transmission 
electron microscopy shows that Spl initially forms a tetramer and subsequently 
assembles multiple tetramers stacked in register at the DNA loop juncture. This finding 
not only provides the physical basis for loop formation but also defines a biological 
process leading to strongly increased concentration of activator protein at the promoter.
In our gel mobility shift assays in which Oligo III of the enhancer that contains a 
putative Sp-1 binding site was used as a labeled probe, we demonstrated that the Spl 
specific oligo was able to compete for the specific binding. Reciprocally, when the Spl 
specific oligo was used as a labeled probe, Oligo III was able to compete for the specific 
binding as well. When the chicken apoA-I promoter DNA fragment (positions -311 to 
+ 19) was used as a competitor in both binding experiments, the apoA-I promoter region
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was able to compete for the specific binding in both gel shifts. We hypothesize that 
interactions between Spl-Spl might play a pivotal role in regulation of the enhancer 
function. To determine if Spl-Spl interactions are at least part of the underlying 
molecular mechanisms responsible for the enhancer function, a series of mutagenesis 
experiments would be needed.
The gel mobility shift assays using oligonucleotides containing a putative HNF-3 
site as the labeled probes showed formation of two specific DNA-protein complexes. 
Specific HNF-3 oligonucleotides were able to compete for the weaker upper band, 
whereas Oligo I, which contains a putative C/EBP binding site, was able to compete for 
the lower band. Specific C/EBP oligonucleotides were able to compete for both the 
weaker upper and the stronger lower bands. Reciprocal experiments using labeled 
specific HNF-3 oligo as probe showed formation of two specific complexes migrating 
together to a position similar to that of the weaker upper band of Oligo II. Both Oligo II 
and specific C/EBP oligo were able to compete almost completely with the upper band 
and partially with the lower band. There are three isoforms of HNF-3: HNF-3a, HNF- 
3(3, HNF-3y. Most likely, the two bands are formed by two HNF-3 isoforms. Oligo II 
contains a weak HNF-3 binding site and probably binds to one of the three HNF-3 
isoforms. To determine which HNF-3 isoform is in the DNA-protein complexes, 
supershift assay experiments using specific antibody against each of the HNF-3 iso forms 
must be done.
Gel shift experiments using Oligo I that contains a putative C/EBP site as probe 
and subsequent reciprocal experiments using specific C/EBP oligo as labeled probe 
suggest that Oligo I contains a weak C/EBP binding site and that C/EBP family proteins
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bind to the enhancer. A preliminary supershift assay using rabbit polyclonal antibodies 
against C/EBPa failed to shift the specific binding, suggesting that it may not be 
C/EBPa but other family members that are involved in the DNA-protein complex 
formation (data not shown).
When Oligo IV that contains a putative HNF-4 binding site was used as labeled 
probe, a specific complex formation was observed but was not competed for by 100-fold 
excess unlabeled specific HNF-4 oligo. When specific HNF-4 oligo was used as labeled 
probe in reciprocal gel shift experiments, no binding was observed at all. These results 
suggest that there is either no, or low level of endogenous HNF-4 nuclear factor in CEF. 
The specific binding in Oligo IV gel shifts is formed by an unknown nuclear factor in 
CEF. Since oligo IV also contains a binding site for AP-2 and a binding site for GATA- 
1, these two factors are obvious candidates.
Results from gel shift experiments using Oligo II and specific HNF-3 oligo as 
labeled probes also suggest that there are some interactions between HNF-3 and C/EBP. 
The 791-bp full-length enhancer contains many putative binding sites for transcription 
factors. Some o f these sites (including HNF-3 site and C/EBP site that are 20 bp apart) 
cluster together. It is not surprising that there are some interactions between them. 
Preliminary competition gel shift experiments using either Oligo I or specific C/EBP 
oligo as labeled probes and 100-fold excess unlabeled Oligo II and specific HNF-3 as 
competitors were performed. Results from these experiments show that both Oligo II and 
specific HNF-3 oligo were able to completely abolish the specific binding in gel shifts of 
specific C/EBP oligo. Of the two DNA-protein complexes formed in Oligo I gel shift 
experiments, Oligo II was able to compete for both bindings, whereas specific HNF-3
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oligo was only able to compete for the weaker upper band, but not the stronger lower 
band (data not shown). For all gel shift experiments, the ultimate confirmation may come 
from gel shift experiments using purified C/EBP, HNF-3 and Sp-1 or supershift assays 
using specific antibodies against these factors.
In summary, we have identified a strong enhancer in the 5’-flanking region of the 
chicken apoA-I gene that could be important for the optimal expression o f the apoA-I 
gene in vivo. We have begun to elucidate the trans-acting factors that mediate the 
enhancer function. The results reported here indicate the complexity o f regulation o f the 
apoA-I enhancer. The enhancer is composed of many modular positive and negative 
elements, all of which are necessary for the enhancer function. The specificity and 
activity of the enhancer rely on binding sites for many nuclear factors including 
ubiquitous transcription factor Spl, liver-enriched nuclear factors HNF-3 and C/EBP, and 
an unknown nuclear factor. The understanding of how chicken apoA-I gene expression is 
regulated in CEF and the differences between mammalian and avian species regarding 
the differential expression of the apoA-I gene may be valuable to develop strategies to 
increase human apoA-I target gene expression.




1. The v-Jun responsive elements in the chicken apoA-I 5’-flanking region have 
been mapped to -311 to +19 upstream of the apoA-I gene transcription start site. It 
appears that there are multiple cis-acting elements that may mediate repression of the 
apoA-I transcription by v-Jun.
2. Gel shift assays and supershift assays demonstrated that neither v-Jun binds to the 
apoA-I promoter directly nor is it involved in the specific protein-DNA interactions 
between nuclear factors from chicken embryo fibroblasts and the apoA-I promoter.
3. Biochemical functional analysis indicates that the DNA binding specificity of v- 
Jun oncoprotein is absolutely required for repression o f apoA-I gene expression. The 
ability o f v-Jun to heterodimerize with diverse partners also contributes to its repressor 
activity. In addition, the amino acid residues 108 to 128 located in the carboxyl terminus 
of v-Jun that contain the independent acidic region III of its transactivation domain are 
also important for its repressor activity.
4. 791-bp enhancer in the apoA-I 5’-flanking region spanning nucleotides -6800 bp
to -6000 bp upstream of the transcription start site was identified and characterized. The 
enhancer is capable of stimulating transcription from both homologous as well as 
heterologous promoters. It is strictly CEF cell-specific. The enhancer consists of many 
positive and negative modular elements, all of which are necessary for enhancer function. 
Sequence information of the enhancer revealed that there are many putative binding sites 
for known transcription factors. Spl, C/EBP, HNF-3, and an unknown nuclear factor 
were found to interact with the cis-acting elements of the enhancer. Interactions among
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nuclear factors bound to different cis-acting elements may contribute to the complexity of 
enhancer regulation.
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